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The development of new therapies for the treatment of lymphoma has been
hampered by the lack of reproducible and faithful in vitro models. This has
been a particular problem with the relatively slow growing types of which two
broad groups are considered here - namely the low grade B cell non-
Hodgkin's lymphomas and Hodgkin's disease.
This thesis describes the development of a culture system using a stromal
cell layer, anti-CD40 and two cytokines - human interleukin 3 (IL3) and
human interleukin 10 (IL10) which has resulted in the in vitro expansion of
low grade B cell malignancies with retention of some of the morphological
and immunophenotypical features of the parent tumour and in addition a
growth rate similar to that found in vivo. This system was able to support
the growth of Hodgkin's lymphoma - both lymphocyte predominant and non
lymphocyte predominant subtypes. Molecular analyses of these cells
suggested a B cell origin in most cases and cell sorting using flow cytometry
for CD30 positive (CD30+ve) cells revealed the presence of Reed Sternberg
cells (RS cells) or lymphocytic and/or histiocytic (L + H) cells in the CD30+ve
cell sorts.
A variant of this culture system using human interleukin 4 (IL4) which has
already been shown to support the growth of follicle centre lymphoma was
found to upregulate CD80 (B7-1), creating the opportunity to assess the
potential for an immunotherapy based approach, as the expression of this
accessory antigen is thought by some to be crucial to the development of an
adequate immune response. This was tested in a mixed lymphocyte
reaction - firstly using allogeneic lymphocytes and then with autologous
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ones against lymphoma cells which prior to culture did not express CD80,
and then with cultured cells which did. Cells cultured using IL3 and IL10
also expressed CD80 although to a lesser degree and the potential for these
cells to elicit mixed lymphocyte responses was also assessed.
The IL3/IL10 anti-CD40 stromal cell system was then used to assess
conventional chemotherapeutic drugs and the findings were compared to
those in a transformed follicle centre lymphoma cell line.
The knowledge that the anti-apoptotic protein Bcl-2 prevented intracellular
repartitioning of calcium lead to the assessment of calcium channel blocking
drugs acting at two sites (1) the cell membrane (nimodipine) and (2) the
endoplasmic reticulum (dantrolene and azumolene). These were initially
tested in various lymphoma cell lines with differing levels of bcl-2 expression
and then in primary lymphoma culture. The effect of these drugs alone and
in combination with cytotoxic agents was compared and the in vitro cytotoxic
activity of dantrolene and azumolene described.
The contribution of such a system for primary lymphoma culture to the
assessment of therapy - both pharmacological and immunotherapeutic is
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" the eye shall not be sated from seeing, nor shall the ear be filled from
hearing. That which has been is the same at that which will be, and that
which has been done is the same as that which will be done, and there is
nothing new under the sun. There is a thing of which (someone) will say,
'see this, it is new.' It has already been for ages which were before us."
Ecclesiastes (Kohelet) 1. 8-10.
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1. LYMPHOMA - HISTORICAL PERSPECTIVES,
CLASSIFICATION AND TREATMENT OUTCOME - WITH
SPECIAL EMPHASIS ON LOW GRADE B CELL AND
HODGKIN'S LYMPHOMA
1.1 : Background and classification of Lymphoma
Lymphoma - malignant disease arising from lymphoid tissue has
confounded pathologists and clinicians for the past 150 years,
with attempts being made to link the features seen at microscopy
with the overall clinical behaviour of disease in an individual.
In 1832 Thomas Hodgkin gave a clear description1 of a primary
lymphoid disorder involving the spleen and lymph nodes. Not all
cases were of the lymphoma now eponomously linked to him but
some clearly were. In 1845 Bennet described a disorder which
linked peripheral blood leukocytosis to enlargement of lymph
node, spleen and liver. It was not until 1864 that Virchow used
the term lymphosarcoma to encompass Hodgkin's and non-
Hodgkin's lymphomas linking these conditions1, and in 1871
Billroth used the name 'malignant lymphoma' as a loose term to
describe these diseases. Sternberg in 1898 having described the
presence of tuberculosis in the context of large multinucleated
cells which now carry his name felt that Hodgkin's disease was an
atypical form of tuberculosis. By 1901, Sir Frederick Andrewes of
St Bartholomew's Hospital, London dismissed this and felt it was a
discrete entity, Dorothy Reed went further to suggest that it was
able to metastasise - pushing it towards classification within
malignant disease and in 1931 Warthin described it as being a
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neoplasm1. Gordon2 in 1932 innoculated rabbits intra cerebrally
with Hodgkin tissue producing encephalitis suggesting a
transmissible agent. Although similar effects could be produced
by benign lymphoid tissue infected with trypanosomes, but not
normal benign tissue, the failure to transfer the encephalitis from
one rabbit to another detracted from the finding.
Maximow1 felt that lymphoid tumours arose from pluripotential
stem cells which he termed reticulum cells, and the tumours
arising from them - reticuloses. In the United States Brill, Baehr
and Rosenthal described a clinical entity in 19253 - clearly follicle
centre lymphoma and Symmers4 described follicular adenopathy
and splenomegaly in 1927, this acquired the eponym Brill
Symmer's disease, although some of the cases Symmers
described included other causes of lymph node enlargement. The
disease was eventually fatal with an aggressive form arising after
several years of relatively asymptomatic activity.
The balance between those who believed that lymphomas were
just results of the same primary process which could pass from
one form to another, or descrete entities, shifted back towards the
latter with Robb-Smith in 1938 in his classification of lymphoid
disorders identifying follicular reticulosis and Hodgkin's disease as
well as a variant which would become known as Hodgkin's
Paragranuloma and eventually lymphocyte predominant
Hodgkin's lymphoma.
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Paragranuloma and Granuloma were names applied by Jackson
and Parker to types of Hodgkin's lymphoma and their conclusion
that cases of paragranuloma which failed to evolve into granuloma
may be considered to be a separate disease can be seen as an
early attempt to separate Lymphocyte Predominant Hodgkin's
Lymphoma (LP-HL) from the other types.
Attempts to separate the various lymphomas on clinical grounds
were further enhanced with Sir Ronald Bodley Scott suggesting
that there were 'several distinct morbid processes each with a
different clinical course'1. Rappaport et al suggested considerable
variability within the clinical group of follicle centre lymphoma and
also distinguished Hodgkin's disease from other lymphomas. In
1966 his classification separated lymphomas into diffuse or
nodular types with a specific Hodgkin's type. Lukes and Butler
subdivided Hodgkin's lymphoma into 6 types with the Rye
classification in 1965 - reducing this to 4 main types. The staging
system which was adopted for Hodgkin's lymphoma was devised
at Ann Arbor in 1971, with the Cotswold's modification5 introduced
in 1989 to further designate bulk disease, and assist in the
classification of complete responses, bringing in the term CR(U) -
uncertain complete remission - when clinical remission existed in
the presence of uncertain radiological features. The most recent
attempt to classify lymphoma6 - the Revised European, American
Lymphoma Classification (REAL) has essentially left the
classification of Hodgkin's lymphoma unchanged - maintaining
lymphocyte predominant Hodgkin's lymphoma within the group
16
and adding a further provisional entity Lymphocyte Rich - classical
Hodgkin's.
Agreement as to how to classify the non-Hodgkin's lymphomas
has been less forthcoming. In 1942 Gall and Mallory7 classified
NHI into 3 main groups: 1) Follicular, Lymphosarcoma
Lymphocytic (CLL); 2) Lymphosarcoma Lymphoblastic; 3)
Reticulum Cell Sarcoma (plasma cell derived). In 1966 Rappaport
introduced his morphology based classification and in 1968 - the
concept of deriving malignancies from B or T cell precursors was
introduced and the germinal centre cell origin of follicle centre
lymphoma was exemplified by Lennert in 1971. Lukes and Collins
introduced a classification based on B or T cell origin and on
morphology in 1974. Lennert et al more influenced by clinical
entities described subtypes again based on B or T cell origin. The
division into low and high grade tumours was proposed by Bennet
and in 1974 a group of pathologists at Kiel maintained this division
placing tumours derived from T or B cell sources in a low or high
grade category1. The number of competing classifications lead to
an attempt to work out a conversion system between them. This
was known as the Working Formulation - clinical division being
into low, intermediate or high grade - with each grade having
prognostic significance with different subtypes listed within each
group. While 'clinician friendly' - and useful for therapy planning,
this formulation which was never intended as a classification as
such failed to take account of aetiology and derivation of the
various tumours and the recent description of new clinical entities
e.g. Mantle Cell Lymphoma, Mucosa Associated Lymphoid Tissue
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Tumours, CD30+ve Anaplastic Large Cell Lymphoma and Primary
Mediastinal Large B Cell Lymphoma. The failure of any of the
current systems to have gained widespread acceptance and the
realisation that not all the subtypes classified under the various
schemes can be reproducibly classified as such by different
pathologists encouraged the establishment of what has been
termed the REAL classification6. This lists clinical entities with
common morphology, behaviour and immunological and in some
cases genetic similarities. It leaves some areas unclassified,
inserts provisional entities and makes the grading of tumours
optional. The discovery that some 'low grade' tumours like mantle
cell lymphoma8 (centrocytic-Kiel) have very poor prognoses much
worse than follicle centre lymphomas has suggested that each
tumour be graded separately e.g. follicle cell lymphoma - grade 1-
3 - rather than lumped in a group which presumes a degree of
clinical aggressiveness. Whether sufficient agreement can be
reached to allow the adoption of this scheme remains to be seen,
but its formal recognition of lymphoma entities outside the older
classifications is certainly an advantage and its acceptance by
pathologists and clinicians may well allow easier comparisons of
clinical outcome to be made.
Clinical outcome of low grade B cell lymphomas and Hodakin's
Disease
The low grade B cell lymphomas include follicle centre
lymphomas, lymphoplasmacytoid lymphomas and small cell
lymphocytic lymphomas (REAL classification). Follicle centre
lymphoma is the commonest and the tendency of all is to relapse
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and remit. 40 years ago median survival was expected to be
about 5 years9. Transformation to high grade histology was
known to supervene. Median survival in the last 5-10 years has
now increased to 9-10 years9. Retreatment following initial
relapse normally results in further remission each remission
lasting 2-3 years unless transformation should occur, when the
median survival falls to 8-10 months. Most patients present with
stage lll/IV disease (75%), those presenting with stage I or II have
a better outcome. In these patients involved field radiation and
multiagent chemotherapy (cyclophosphamide, vincristine and
prednisolone) has resulted in an 83% relapse free survival at 5
years10.
For advanced disease there appears to be little advantage of
multidrug treatment over single agent chlorambucil11. The
addition of an anthracycline in initial treatment appears to have
doubtful value except for those within an excess number of blast
cells9. Interestingly, failure to respond to a treatment on the first
occasion does not preclude response on a subsequent
occasion10. After 1st relapse median survival is in the region of 5
years10.
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Survival from recurrences of patients with follicular non-Hodgkin's
lymphoma
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The poor long term outlook of these conditions has encouraged
the search for alternative approaches. The purine analogues
fludarabine and cladribine - both deoxyadenosine analogues are
taken up by lymphoid cells where they induce apoptosis12. In
previously treated patients (3 regimens on average) treatment
with fludarabine has yielded a response rate of 48%13, Interferon
a has a 40% response rate in untreated patients9 and
maintenance treatment with interferon to people in remission
induced by chemotherapy prolongs disease free survival9. As this
group of diseases is chemosensitive, high dose intensification with
cyclophosphamide and total body irradiation for patients in 2nd or
subsequent remission has been offered14 with purged autologous
bone marrow support. This treatment has resulted in a 5% toxic
death rate and 5% late death rate from secondary
myelodysplasia/acute myeloid leukaemia15. Although prolonged
remissions occur whether this treatment can be considered
curative remains an open question.
New approaches using targeted monoclonal antibodies16 have
been encouraging and the activity of interferon has enhanced the
cause of immunotherapy. The importance of bcl-2 in the
suppression17 of apoptosis that occurs in these tumours has
encouraged the development of antisense oligonucleotides
targetted to the translocation breakpoints that result in its
upregulation.
Improvements in in-vitro modelling would aid the assessment of
new treatments and the primary culture of low grade lymphoma
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described has allowed a potential immunotherapy based strategy
and a pharmacological approach to be examined in this thesis.
1.3 Hodakin's Lymphoma
The clinical outcome in HL remains better than low grade NHL.
Median survival at a single centre18 has been reported as 18
years. The progression of the disease from one nodal group to
another has lent itself to be use of irradiation to encompass the
likely sites of nodal disease. The median survival following
relapse is the same regardless of the modality of initial therapy.
The lymphocyte predominant group appears to have a better
prognosis than the rest19 - accounting for only 7% of the total
cases, it presents at an earlier stage with a 12 year survival of
82%, however 12% of patients developed secondary
malignancies over 13 years which is high, 1/3 being high grade
undifferentiated B cell lymphomas. Chemosensitivity to first line
treatment governs the likelihood of response to subsequent
conventional treatment18. The original MOPP like treatments
achieve complete response rates of 70% in advanced disease;
70% of these will be durable. For those who relapse after initial
complete response 81% will respond again.
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Addition of an anthracycline to the primary treatment has
improved the survival with MOPP-ABVD or ABVD alone being
superior to MOPP - 5 year survival being 75, 73 and 66%
respectively20. Failure to remit carries a poor prognosis with a
median survival of 1.4 years18.
The role of high dose treatment in relapsing patients is unclear.
The timing of its use has depended on the enthusiasm of the
treating clinician. Poor prognosis suggested by those whose 1st
remission is less than 1 year - would appear to be a reasonable
indication18, however failure to respond to treatment does not
imply no benefit from high dose chemotherapy as some of these
patients will derive prolonged disease free survival and thus some
feel it should be given to those refractory to conventional
treatment21, median progression free survival in those failing to
attain complete remission being 42% at 3.6 years22.
The tendency to relapse with chemosensitive disease is
reminiscent of the situation with low grade NHL. However, the
time scales are different with median life expectancy with HL
being about twice that of low grade NHL. Both tumours have
generally low growth rates - a situation which is difficult to mimic
with cell lines. In HL most of the cells in the affected node are
benign23 with perhaps only 1-2% being malignant cells a situation
which is unusual in cancer.
New approaches to treatment have included monoclonal
antibodies targeted at the Reed Sternberg-Hodgkin's (RS-H) cells
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using anti-CD30 and anti-CD2524 conjugated with saporin.
Excellent responses have been seen but as the antibodies to date
have been murine repeated exposure leads neutralising
antibodies forming and subsequent relapse. The role of antibody
treatment in minimal residual disease remains to be investigated.
Attempts to understand the biology of the RS-H cells and the
relationship between LP-HL and the rest are hampered by poor in-
vitro models. The stromal cell system described has allowed
further analysis of primary cultured cells to be made and will
hopefully lead to an enhanced understanding of the disease.
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2. IN VITRO CONTROL OF LYMPHOCYTE PROLIFERATION
AND DIFFERENTIATION - A BASIS FOR DESIGNING THE
STROMAL CELL SYSTEM
2.1 Introduction
This chapter reviews the various triggers and cytokines required
to induce B cell proliferation and differentiation and concludes with




The CD40 antigen has an important role in B cell activation,
proliferation and class switching25, it is a 47-50KD glycoprotein, a
member of the tumour necrosis factor (TNF) ligand superfamily26
and exists in a soluble form. As well as its presence on B cells it
has also been detected on epithelial cells, basophils, and follicular
dendritic cells27, it is upregulated after activation and down
regulated as B cells undergo terminal differentiation. CD40 may
be upregulated by IL4, IgM, and anti-CD4028. Ligation leads to
proliferation of anti IgM crosslinked or IL4 stimulated B cells.
Its natural ligand (CD40L, gp39) is found on T cells29, failure of
this to bind appropriately leads to the hyper IgM syndrome and the
lack of normal B cell proliferation in vitro. The CD40 antigen in
these patients is normal29.
The crosslinking of CD40 - either using antibody directed against
it or the CD40L leads to the suppression of apoptosis30. This
effect is partly mediated by bcl-2, but as constitutive bcl-2
production does not rescue slg mediated apoptosis another
mechanism must be required. CD40 signalling appears to
required tyrosine phosphorylation25.
CD40 binding is important in modulating the response of B cells to
cytokines. Benign tonsillar B lymphocytes will undergo long term
proliferation when CD40 ligation occurs in the presence of
IL431.32 Proliferation has also been seen in B CLL cells in such a
system33 as well as follicle centre lymphoma34. B cell precursors
29
will proliferate when other cytokines are used as well e.g. IL3,
IL1032. Enhancement of the response is seen with IL3 rather than
with IL4 or IL1032 and combined stimulation of B cell precursors
with IL3 and IL10 is similar in terms of growth rate to IL3 alone. It
has been suggested that IL3 is acting on more immature cells
than IL4 or IL1032 and indeed maturation is not prominent an
IL3/anti-CD40 system.
Mature B lymphocytes have been grown using CD40L rather than
stromal cell bound anti-CD4035 and here the maximal response to
IL4 or IL10 is similar when studied for the first 7 days. Ig secretion
is regulated by CD4036 with combinations of cytokines leading to
different levels and isotypes of Ig secretion.
The role of CD40 in immune regulation is characterised by its
effect on the CD80 (B7) system. CD40 binding by its ligand leads
to CD80 (B7.1) and CD86 (B7.2) upregulation28 two important
accessory molecules whose effects will be discussed later.
Blockade of CD40L - prevents this upregulation. CD40 has also
been demonstrated to be present in Hodgkin and Reed Sternberg
(RS-H) cells37 - this has been demonstrated in RS derived cell
lines and in primary H-RS cells. Interestingly, in these cells it did
not lead to proliferation or CD80 induction.
In summary, CD40 - via its ligand CD40L or via crosslinking by
anti-CD40 Ig leads to clonal expansion, Ig production, isotype
switching, and B cell proliferation. These effects can be
influenced by exposing the lymphocytes to various cytokines. It is
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also expressed in RS-H cells where it may induce cytokine
production but does not seem to induce proliferation.
Cytokines and B Cell Proliferation and Differentiation - IL3. IL4
and IL10
The control of B lymphocyte proliferation and differentiation has
been known to be under the control of T cells. Follicle centre
lymphomas have been shown to be stimulated to grow under the
influence of CD4+ T cell clones38. Lymphomas cells expressing
t(14;18) cultured in such a way vary in morphology depending on
the T cells - some become plasma cell like, others become small
with little cytoplasm. T cell contact is required for proliferation and
IL2 and IL4 secreted by them appeared important to support
growth and differentiation. 2-3 weeks was the maximum period
that this would occur for.
IL3
Interleukin 3 - this T cell derived cytokine39 binds to a receptor
with 2 subunits, the alpha subunit is specific for IL3 the beta
subunit is shared with various other cytokines40. It acts on a wide
spectrum of haemopoietic cells41 - causing the growth of
erythroid, myeloid and megakaryocytic lines. It has been used to
support patients with chemotherapy induced cytopenia41. In B
cells its actions are complex, there is evidence that it is a growth
factor and that it may cause differentiation42. The stimulation is
comparable to that achieved with IL4 and differentiation occurs
through growth - although some may be via IL6 secretion42. The
effect of IL3 on CD40 activated B cells is to promote
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differentiation. Using an anti-CD40 system throughout with Ltk-
cells Ig synthesis rises43.
Normally the IL3 receptor is only transiently expressed,
expression may occur in late stage malignant cells e.g. myeloma,
follicle centre lymphoma42. While it has been found to be a
growth factor for follicle centre lymphoma44 where the IL3 receptor
has been found in a cell line derived from such a lymphoma,
whose main growth factor was IL3, suggesting that this lymphoma
may be retaining characteristics of an earlier stage of
development, there is also evidence that IL3 suppresses follicle
centre lymphoma growth and that when lymphoma cells are taken
from patients and are found to express the IL3 receptor addition of
IL3 leads to a reduction in 3H thymidine uptake45.
]L4
This TH2 derived cytokine46-47 elicits responses from
macrophages and fibroblasts as well as B cells. B cells, activated
either by S. aureus Cowan (SAC), or anti-IgM48 or anti-CD4049
will proliferate under its influence. Germinal centre cells alter their
morphology49 whilst normal B cells proliferate without
differentiation. SlgD+ blasts proliferate in preference to slgD"
(activated cells), long term proliferating cells lack germinal central
markers, (CD10, CD38) the SlgD" (see Figure 1) will proliferate for
30 days, the SlgD+ cells for 60 days.
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Figure 1: B cell precursor differentiation and proliferation
B Cell Precursor
-> Differentiation






Some of the SlgD- pool is renewed by the SlgD+ cells49. In
malignant culture systems IL4 alone with CLL cells has been
found to block apoptosis by upregulating bcl-260.
I Lf 0
This cytokine - originally termed cytokine synthesis inhibiting
factor51, is a Th2 derived cytokine with varying effects on the T
cells, cells of the monocyte/macrophage series and B
lymphocytes.
It is homologous to the open reading frame in EBV, BCRF-152.53.
Synthesized by CD4+ T cells, it inhibits the cytokine synthesis by
T cells and has an immunosuppressive role51. It also inhibits
monocyte costimulating activity by inhibiting the upregulation of
CD8054. In contrast, its effects in B cells tend to be stimulatory.
EBV transforms B lymphocytes and proliferative control depends
on IL1055. Mature B cell lines produce IL10. IL4/anti-CD40 fails
to induce IL10. IL10 and IL4 are able separately to induce B cell
growth following activation with anti-CD4056. However, after 1 - 2
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weeks the main effect of IL10 is to induce terminal differentiation,
by 21 days - no proliferation occurs56. As anti-CD40 has growth
promoting activity and IL4 but not IL10 promotes CD40
expression, this may be part of the reason. IL10 is also able to
induce proliferation of SAC stimulated cells57.
Germinal centre cells undergo spontaneous death in-vitro via
apoptosis58. However, IL10 is able to increase bcl-2 levels and
cell viability can be prolonged at 7 days by reducing spontaneous
death from 75% to 40%. Germinal centre cells - produce bcl-2
poorly, neither IL2 nor IL4 can prolong their life. This raises the
question as to whether IL10 may play a role in development of
follicle centre cell lymphomas following bcl-2 rearrangement. The
differentiating effects of IL10 on B cell blasts grown on marrow
stroma has been confirmed59. Blocking the effects of endogenous
IL10 fails to alter CD40 induced B cell proliferation56.
Sustained immunoglobulin production occurs (also with IL3). The
combination together maximises the effect, the effect on
differentiation being independent of the effect on proliferation.
CD38 is upregulated and CD20 downregulated and the cells
become plasma cell like59. Endogenous IL10 is responsible in
part for differentiation of B lymphocytes49. An EBV
lymphoproliferative disease derived cell line produces IL1060 -
interestingly no BCRF-1 is transcribed, therefore autocrine control
by hlL10 is suggested.
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2.4 Rationale for cytokine combinations in the stromal cell system
Low grade B cell lymphomas, grow very slowly - indeed their
growth rate may not be different from benign lymphoid tissue,
however, delay in undergoing apoptosis leads to the accumulation
of long lived cells61. Failure to undergo apoptosis means there is
a loss of an important mechanism to keep cell numbers
constant62. Many attempts to grow low grade lymphoma in-vitro
have concentrated on achieving cell division33.34.44, but it is
necessary to ensure that the division rate and morphology be
retained if the model is to be representative of in-vitro conditions.
The bcl-2 oncoprotein is one of a family of apoptotic suppressor
proteins which is upregulated at various stages of normal
lymphocyte development63. Persistent upregulation may be one
important mechanism by which malignant B cells retain their
advantage over their benign counterparts62. It is important in
lymphoma expressing bcl-2 that this expression continue during
in-vitro culture.
The cytokines described above are unable to provide the desired
effect of slow growing, mature, malignant lymphocytes and
combinations of cytokines with predominant proliferating or
differentiating activity yield improved results. The role of T cells in
regulating B cell growth might be utilised so long as they did not
overgrow the B cells.
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The following systems were investigated: (1) IL4/anti-CD40 - all
its effects on growth and phenotype are already described34 and
(2) IL3/IL10 anti-CD40.
The relative success of the IL3/IL10 anti-CD40 stromal cell system
in culturing low grade B cell lymphoma and the realisation that
there is evidence that Hodgkin's lymphoma is B cell derived at
least in some cases prompted the investigation of this system in
Hodgkin's lymphoma as well.
36
CHAPTER 3
THE STROMAL CELL CULTURE SYSTEM
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3. THE STROMAL CELL CULTURE SYSTEM
3.1 Introduction
This chapter describes the setting up of a stromal cell system for
the primary culture of low grade B cell and Hodgkin's lymphoma.
The rationale for the system, and the various cytokines used are
described as is the preparation and storage of the lymphoma
tissue. Techniques to verify the nature of the cultured cells are
explained and comparison is made with the culture of benign
lymphoid tissue.
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3.2 List of tumours and benign lymphoid tissue taken for culture
Non-Hodgkin's Lymphoma
Tumour Histology (REAL) Classification5
L2 Follicle centre lymphoma, follicular, grade 1 (FCL)
L3 B-cell small lymphocytic lymphoma (SLL)
L4 Follicle centre lymphoma, follicular, grade 1
L5 Follicle centre lymphoma, follicular, grade 1
L6 Splenic marginal zone B cell lymphoma with areas
of transformation to diffuse large B cell lymphoma
(SMZL/DLBCL)
L7 Follicle centre lymphoma, follicular, grade 1
L8 Follicle centre lymphoma, diffuse, grade 1
L9 B-cell small lymphocytic lymphoma
L10 Follicle centre lymphoma, follicular, grade 1
L11 Follicle centre lymphoma, follicular, grade 1
L12 Follicle centre lymphoma, follicular, grade 3
L13 Follicle centre lymphoma, follicular, grade 1
Hodgkin's Lymphoma
L17 - Lymphocyte predominant (LP)
L18 - Mixed cellularity (MC)
L20 - Lymphocyte predominant with a single area of
transformation to diffuse large B cell lymphoma
L25 - Mixed cellularity
L27 - Nodular sclerosing (BNLI grade 2) (NS)
L28 - Nodular sclerosing (BNLI grade 1)
40
Benign Lymphoid Tissue
R1 - Benign reactive lymph node.
T1 - Tonsil removed at tonsillectomy.
Preparation of cells for culture
The lymph nodes and tonsils studied were all prepared similarly.
Samples were taken at biopsy or in the case of the tonsillar
control at tonsillectomy. The samples were processed in a
laminar flow hood. The tonsils were sprayed using 70% ethanol
preceding dissection. The tonsil/lymph node was then dissected
in a RPMI based medium (RPMI base) consisting of RPMI 1640
400ml with glutamine, Fetal calf serum (Gibco, Paisley, Scotland)
40ml, Hepes 25mmol/L (Gibco), Penicillin and Streptomycin
solution (Gibco) 5ml.
A cell suspension was prepared and this was centrifuged at 600g
for 5 minutes at 25°C before washing in RPMI base a further two
times. The solution was now ready for centrifugation on Ficoll
Hypaque (Lymphoprep, Nycomed Pharma, Oslo, Norway) at
1000g for 25 minutes at 25°C. The mononuclear fraction was
removed and washed twice. The pellet was then resuspended in
10ml RPMI base, and a cell count was carried out manually using
a haemocytometer. Base line immunophenotyping was then
carried out. The cells were then spun down and a freezing
mixture consisting of RPMI 70ml, Fetal Calf Serum 20ml,
Dimethylsulphoxide (DMSO) 10ml (Fluka) was added dropwise to
ensure a final concentration of 2 x 107 cells/ml. The cells were
then vortexed and aliquoted into 1ml Nunc freezing tubes. These
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were put on dry ice for 40 minutes before placing in liquid
nitrogen. The vials were numbered according to the tumour and




Preparation of fibroblast monolayer
The stromal cells used were mouse fibroblast Ltk- cells,
transfected with Fcyrll receptor-CD3264, which is the monocyte Fc
receptor. The receptor has 61% homology with the murine IgGi
receptor. The stromal cells were grown in Falcon 100ml flasks
(Beckton Dickinson) in a HAT medium, to ensure that the growing
fibroblasts did express the Fc receptor. The medium used
consisted of RPMI 1640 with glutamine 450ml, Fetal Calf Serum
50ml (10% vd/voi), HAT (1:200, Sigma).
The cells grew as an adherent monolayer; on reaching
confluence, the medium was aspirated and they were freed using
2 millimole/litre EDTA, at 37°C for 5 minutes. The cells were then
aspirated and centrifuged at 600g, 25°C for 5 minutes. They were
then resuspended in 48ml of the HAT medium and vortexed
vigorously. 1 ml was placed in each well of a 24 well culture plate
(Beckton Dickinson). The cells were then allowed to grow to 80-
90% confluence at 37°C with 5% CO2, before been irradiated to a
dose of 75Gy. Following irradiation, growth did not stop
immediately and indeed the monolayer often became confluent
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over the next 48-72hrs. The Fc receptor would act as anchor for
anti-CD40 - essential for establishing lymphocyte proliferation.
Resuspension of lymphoma cells for culture
These were initially resuspended in RPMI base medium in which
they were washed twice to remove DMSO. The cells were then
resuspended in a holding medium of Dulbecco's without phenol
red (Gibco) with supplemented bovine serum albumin 10g/L
(Sigma) and human immunoglobulin 0.5g/L (Sandoglobulin,
Sandoz). The cells were left in this medium for a maximum of
8hrs at 4°C. Viability was assessed by 0.1% trypan blue (Sigma)
exclusion. It was usual to discard vials with viabilities of less than
70%.
The irradiated fibroblasts were taken in their 24 well plates and
the supernatant (containing HAT) was aspirated and 1-2ml of
RPMI base medium put in each well. This was then aspirated
prior to the plating out of the lymphoma cells. The lymphoma cells
were counted and resuspended to ensure a viable cell count of 5
x 105/ml in a growth medium consisting of Iscove's modified
Dulbecco's medium without FCS (Gibco) with 50mg/L human
holotransferrin, bovine serum albumin 5g/L; bovine insulin 5mg/L;
long chain fatty acids (cis 9 octadecenoic, all cis 9, 12,
octadecadienoic, and hexadecanoic acid all at 1 mg/L) ( all from
Sigma, FCS 20ml/L (vol/vol), penicillin and streptomycin (Gibco),
Gentamicin 40mg/L (Roussel) and Amphotericin 2.5mg/L (Squibb)
anti-CD40 1mg/L (Serotec) and various cytokines IL3 20pg/L
(kindly provided by Amgen Inc., Thousand Oaks, California); IL4
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46pg/L (kindly provided by Schering Plough Research, Bloomfield,
New Jersey) and IL10 100pg/L (kindly provided by Amgen Inc.,
Thousand Oaks, California).
Usually 8 x 106 lymphoma cells were taken suspended in 16ml of
growth medium with supplemented cytokines and anti-CD40 and
pipetted into 8 wells (2ml per well; 106 cells per well).
Depending on their speed of growth the wells had 1ml of growth
medium aspirated at day 7-10 and fresh medium with cytokines
supplemented but this time only 0.5mg/L CD40 was added. After
14 days the cells were gently pipetted, washed and resuspended
in fresh medium to plate down on a new monolayer.
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FIGURE 1: THE IL3/IL10 ANTI-CD40 STROMAL CELL CULTURE SYSTEM
IL10 and IL3
f





3.6 Depletion of T and virgin B lymphocytes
In some experiments it was decided to deplete the cell
suspensions of T lymphocytes and sometimes the lgD+ B
lymphocytes as well - this was the case to where CD80
expression was being induced using IL4/anti-CD40.
2 x 107 lymphoma cells were taken prior to culture and were
incubated with monoclonal anti-IgD at a concentration of
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100|il/lml/107 cells, anti-CD8 50|il/lml/107 cells and anti-CD4
250(il/lml/107 cells (all Dako). The amounts of antibody used
were chosen following titration of serial dilutions of the antibodies
with tonsillar lymphocytes. After 30 minutes incubation at 4°C, the
cells were washed twice to remove any unbound antibody, and
Dynabeads (Dynel International, Oslo, Norway) which were
coated with anti-mouse Ig and had themselves been washed in
PBSA to remove any azide preservative, were incubated together
at a concentration of 1 ml/107 cells on a rotating mixer at 4°C for
1 hr. The cells were then removed using magnetic separation and
immunophenotyped as appropriate.
Phenotvping of cells and cell sorting
Cells were immunophenotyped as a baseline prior to culture.
Antibodies were added to cells for 30 minutes at 4°C in 96 well
plates and then centrifuged at 600g for 1 minute at 4°C, they were
then resuspended in IOOp.1 PBSA prior to re-centrifugation, before
fixing in 250pl of 1% paraformaldehyde. CD30 based cell sorts
were carried out by taking 2 x 107 cells of cultured Hodgkin's
lymphoma on day 15 and incubating them with 200pl of anti-CD30
FITC (Dako), the cells were then sorted using a FACStar Plus cell
sorter with a fluorescence histogram for CD30 FITC (fluoroscein
isothiocyanate) being produced and a marker set against a
negative control. Those cells with fluorescence above a certain
threshold were deemed CD30+ve and collected as such, with the
CD30-ve cells collected separately.
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Figure 2: Diagrammatic Representation of B cell Antigen Expression - only
showing antigens studied In-vltro culture









As can be seen it possible to place the main population of cells by
the combined expression of various antigens e.g. if a majority of
cells express CD10, CD19, CD22 and CD38 they are likely to be
at the germinal centre stage of development, whilst those
expressing CD19 and CD22 to a lesser extent, and lacking CD10
are likely to be less mature.
3.8 Preparation of cells for bcl-2staining
As this oncoprotein is found at various sites within cells,
permeabilization of the membrane is required. Temporary
permeabilization was achieved using the detergent saponin
(Sigma)65. The cells were suspended in 0.3% saponin in
phosphate buffered saline (PBSA) for 15 minutes at 25°C. They
were then phenotyped using anti-bc/-2-FITC (Dako)
(1 Opil/106/1 OOpil) in 0.1% saponin solution for 30 minutes at 25°C.
The cells were then centrifuged and resuspended in PBSA with
1% paraformaldehyde. The negative control (IgG 1, FITC negative
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control, Dako) was prepared similarly for this analysis 5,000
events were surveyed.
3.9 Growth Fraction Assessment
Cells were fixed in 70% ethanol. Ribonuclease A type 1
(Boehringer Mannheim) 100k units/ml was added. Propidium
iodide (PI) 50pg/ml was then introduced. PI fluorescence was
detected at over 580nm. Cells from the fibroblast monolayer were
gated out using forward and side scatter. 2,000 cells were
analysed. Cells with PI fluorescence in the hypodiploid and
diploid G0/Gi peak and the hyperdiploid S + G2 (growth fraction)
were determined on red fluorescence histograms using Lysysll
software.
3.10 Bcl-2 in growing and resting cells fsee Figure 31
Data were displayed using a quadrantic plot:- X axis - FL-1
channel (FITC) (ie: bcl-2), Y axis FL-2 (ie PI). Markers were
placed between the growing and resting cells based on PI staining
and between those that did and did not express bcl-2 (by
comparison with lgG1, FITC - negative control). It was possible to
separate the following into different quadrants - resting cells - bcl-
2- negative (3), resting bcl-2 positive (1), growing bcl-2 negative
(4), growing bcl-2 positive (2).
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Figure 3: Quadrantic plot showing bcl-2/growth fraction relationship
Go G1
3.11 Kappa and Lambda light chain staining
Cells were taken and not blocked with human immunoglobulin, if
they had been they were put in RPMI 1640 at 37°C for 1 hour first.
2 colour fluorescence was used. Polyclonal F(ab)2 antibodies
were used (Dako). They were diluted to 1|il/106/100ml k-FITC, X-
PE, incubated for 20 minutes with the cells (both antibodies
simultaneously).
3.12 Morphological Examination
Cytocentrifugation specimens were prepared. Cells were
harvested from the culture wells and resuspended in PBSA with
0.2% albumin. 100ml of cell suspension containing 105-106 cells
were cytocentrifuged in a Cytospin 3 at 600rpm for 5 minutes.
The slides were then air dried before staining using the May
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Grunwald Giemsa Method. They were then examined under light
microscopy.
3.13 Synthesis of Immunoglobulin
Immunoglobulin synthesised may be confined to the cytoplasm,
expressed on the surface membrane, or secreted. In the germline
state, k and X light chain genes each exist as a number of variable
(V), joining (J) segments and a constant (C) region66. During B
cell development one of the V regions is juxtaposed to one of the
J regions with excision of the intervening DNA. The rearranged
VJ segment together with the C region is transcribed. Intervening
RNA is spliced out to form the final mRNA. Both or only one allele
may rearrange.
Heavy chain rearrangement is complicated by the fact that there
are diversity (D) segments between the V and J regions, DJ
joining occurs first, followed by C-DJ joining.
9 genes correspond to the different Ig subtypes. Class switching
occurs when a rearrangement within this H chain gene cluster
inserts a new constant gene instead of C|i; this allows the
antigenic determinant to be maintained despite a change in Ig
class. Immunoglobulin rearrangements occur in a set order: Ig
heavy chains followed by k light chains, followed by X light chains.
Therefore if a X Ig is secreted all genes will have rearranged,
although the k rearrangement will be non-productive66.
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Rearrangement of the Ig Heavy Chain66
In B lymphocytes, the Vh region contains 3 hypervariable
complementary determining regions - CDRI, II and III and their
relatively conserved framework regions FRI, II and III.
Rearrangement brings FRII and the CDR regions67 into close
proximity allowing a polymerase chain reaction based technique
to look for monoclonal IgH rearrangements. If the two regions are
in the germline state they remain too far apart making generation
PCR IgH products impossible. Such a technique was used to
study the clonal origin of Hodgkin's lymphoma in culture
(described later).
3.14 PCR based technique for the heavy chain rearrangement -
fHodakin's Lymphoma)
Cultured cells were washed twice in PBSA, and DNA was
prepared by phenol/chloroform extraction, following detergent
lysis and proteinase k digestion. The presentation samples had
DNA either extracted from paraffin blocks or from cell suspensions
taken at biopsy.
A highly sensitive semi-nested PCR was performed in a Gene-
Amp PCR system 9600 (Perkin Elmer Cetus, Norwalk CT). The
first amplification was performed using an upstream consensus
primer FR2A67-68 designed from homologous regions within Vh
framework II and a downstream primer LJH that bound to ail
published Jh gene segments. For the initial amplification, 0.5|ig of
genomic DNA was used. For the reamplification, the downstream
primer LJH was replaced by a nested consensus primer VLJH,
with 1% of the initially amplified product being used as a template.
The PCR conditions comprised five initial high stringent cycles at
96°C for 15 seconds for DNA denaturation, at 63°C for 30
seconds for primer annealing and at 72°C for 30 seconds for
primer extension, followed by 35 cycles with the same
denaturation and extension conditions but with an annealing
temperature of 57°C. The reamplification consisted of 25 cycles
of denaturation at 96°C for 15 seconds, annealing to 63°C for 30
seconds and extension at 72°C for 30 seconds. The differences
beside the total number of cycles, the primer usage and highly
stringent annealing temperature between the first and
reamplification, were the concentrations of MgCl2 (1.5mmol/L
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versus 2.0mmol/L) and the amount of each primer (first
amplification with 400ng FR2A, 100ng VLJH; reamplification with
200ng FR2A and 200ng VLJH).
1 Ojj.1 of each amplified product were applied to a 2% agarose gel
and visualised by staining with ethidium bromide.
3.14.1 DNA sequence analysis
The sequencing of the PCR product was performed using an
automated DNA sequencer (Applied Biosystems 373A) by using
the Dye Deoxy Terminator Method for use solely with this system.
The PCR products were passed through a Sephadex G50 column
and after ethanol precipitation the products were sequenced in
both directions using the FR2A and VLJH primers respectively.
Only cases with a complete homology between both sequences
were chosen for comparison with published VJH germ line
sequences. To act as controls, DNA was extracted from mouse
fibroblasts which provided the monolayer, and cultured benign
lymphocytes from a reactive role.
3.15 Preparation of cells for Cytogenetic Analysis (Hodakin's
Lymphoma)
Cells were taken at day 10-15 in culture for cytogenetic analysis.
Whilst still adherent to the fibroblast monolayer they were treated
with colcemid (Gibco) 10p.g/ml for 16hrs before pipetting
centrifugation at 600g for 5 minutes at 20°C. The resultant pellet
was resuspended in 75mmol/L KCL and then incubated for 10
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minutes at 37°C. This was then centrifuged at 600g for 5 minutes
and fixed in 3:1 methanokglacial ethanoic acid, centrifuged and
resuspended in this a total of 3 times. Slides were prepared by
placing a drop of fixed material on a slide, and then left to age for
several days at room temperature and banded using 0.1% trypsin
(Difco, Detroit, USA) for 5-10 seconds and stained with Giemsa
for 1 minute prior to drying and analysis.
3.16 EBV Status and Light Chain Restriction (Hodakin's Lymphoma)
Paraffin sections of all lymph node biopsies were stained using a
streptavidin biotin peroxidase method after heat pretreatment
using monoclonal antibody against latent membrane protein
(LMP) of EBV (Dako). Both cases of LP-HL were stained using
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4. CULTURE OF BENIGN LYMPHOID TISSUE USING THE
IL3/IL10 STROMAL CELL SYSTEM
4.1 Introduction
This chapter examines the effect of long term culture on benign
lymphocytes using the IL3/IL10 stromal cell system. Two sources
of lymphoid tissue are used and sequential analyses of flow
cytometric and morphological data are presented.
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4.2 Phenotvpina benign lymphoid tissue
Table 1: Table of Phenotyping for IL3/IL10 anti-CD40 - Benign Lymphoid Tissue.
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• • • • • •
IgD F(ab)2
(Dako)




















• • • • • •
Cells were taken from two different sources (1) a tonsil (2) a
reactive lymph node. No attempt was made to deplete the T cells.
The cells were grown for 30 days and were still vigorously dividing
when the cultures were discarded at this point. Replating onto
new fibroblasts was carried out at day 15. Cells were taken for
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cytocentrifugation on days 10, 15, 20 and 30. Growth fraction was
assessed at 5 day intervals. Immunophenotyping was carried out
every 5 days - see Table 1. A marker was set based on the
negative control, percentages are given compared to this.
4.3: Results
Table 2: Immunophenotyping Results ■ Tonsil (T1)
Antibody Day 1 Day 5 Day 10 Day 15 Day 20 Day 30
Gi 4 2 1 0 2 2
CD3 35 13 13 12 19 13
CD10 14 3 3 5 6 4
CD14 9 _ 2 _ 3 3
CD19 67 75 45 66 47 64
CD22 59 69 59 61 44 20
CD38 38 9 1 1 1 7
IflD 30 - 40 _ 12 19
k/K Both . Both _ Both Both
CD15 23 _ 15 _ 24 18
CD30 6 _ 28 _ 33 31
GF 14 38 17 21 16 14
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Table 3: Immunophenotyping Results - Reactive Node R1
Antibody Day 1 Day 5 Day 10 Day 15 Day 20 Day 30
Gi 1 0 0 0 2 2
CD3 60 26 18 21 45 35
CD10 15 1 2 0 3 4
CD14 7 _ 2 . 1 27
CD19 44 69 35 48 15 34
CD22 38 69 68 57 21 3
CD38 19 2 2 4 6 3
IqD 19 _ 31 _ 6 2
Kfk Both Both Both Both Both Both
CD15 19 _ 11 17 _ 1
CD30 4 _ 11 9 _ 1
GF 13 38 17 23 25 10
The immunophenotyping confirmed a B-cell expansion. There
was no evidence of T cell (as judged by CD3) or monocyte (as
judged by CD14) overgrowth suggesting that depletion of these is
unnecessary in this system. Overall, the percentages remained
fairly constant and close to the in-vivo situation (day 1). It was
disappointing to see the loss of the germinal centre cell phenotype
(CD10, CD38). In both cases loss of these cells within the first 5
days was not accompanied by their return later in culture.
CD19 and CD22 - CD22 is a more restricted B-cell marker than
CD19. Both remained throughout culture but both diminished
after a surge in the first 10 days although evidence of a rise in
CD19 occurred at day 30. IgD positive cells fell after an initial
surge - it did not appear that any lgD+ cells were proliferating as
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has been suggested as the growth fraction remained high in the
last 15 days despite the disappearance of IgD bearing cells.
k and X - No evidence of light chain restriction occurred nor
would it be expected in benign tissue.
CD15 and CD30 - These two markers were studied as they were
present Reed Sternberg - Hodgkin's cells69-™ and it was important
to know if they appeared in benign lymphoid tissue in culture.
CD15 - A granulocyte marker, not present in macrophages or
lymphocytes or platelets, but seen in promyelocytes and
myelocytes.
CD30 - (Ki-1 )24-70 - A membrane protein seen in RS-H and a
varying proportion of activated T and B cells. It is seen in RS-H
cells and anaplastic large cell lymphomas.
In the reactive node, there was no suggestion of upregulation
during culture, however, in the tonsil CD30 did upregulate to a
degree this may have represented activation by CD40. The high
initial expression of CD15 is more difficult to explain.
Growth Fraction - This remained high in both samples generally
exceeding the initial growth fraction.
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Cvtocentrifuaation Specimens
Blast cells and centrocytes were present from day 10. Reduced
numbers of blast cells were present by day 20 and numerous
plasma cells with increasing cytoplasm were seen from day 20.
This is in line with the differentiating effects of IL10 (see Prints 1 -
6).
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Prints 1-3: Cytocentriguation specimens from a reactive node:




Prints 4 - 6: Cytocentriguation specimens from a tonsii:
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LEGENDS FOR PRINTS OF BENIGN LYMPHOCYTES IN CULTURE
Prints 1 - 3: Cells cultured from reactive node (R1) shown at day 9
(Print 1), day 15 (Print 2) and day 30 (Print 3). The cells
show increasing plasma cell differentiation becoming
larger with increasing amounts of cytoplasm.
Prints 4 - 6: Cells cultured from a tonsil shown at day 9 (Print 4), day
15 (Print 5) where they can clearly be seen clumped
around a central mouse fibroblast and day 30 (Print 6).
Again plasma cell differentiation is prominent.
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Table 4: Cytocentrifugation specimens





































The IL3/IL10 CD40 stromal cell system supports lymphocyte
culture for at least 30 days. The proliferation is predominantly B
cell with no evidence of light chain restriction. Morphology shows
increasing numbers of plasma cells and centrocytes with reducing
numbers of blast cells. The germinal centre cell phenotype is lost
rapidly. There is little upregulation of CD15 and CD30.
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CHAPTER 5
CULTURE OF LOW GRADE B CELL LYMPHOMA
USING THE IL3/IL10 STROMAL CELL SYSTEM -
COMPARISONS WITH IL4/ANTI-CD40
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5. CULTURE OF LOW GRADE B CELL LYMPHOMA USING
THE IL3/IL10 STROMAL CELL SYSTEM - COMPARISONS
WITH IL4/ANTI-CD40
5.1 Introduction
8 Low grade B cell lymphomas were studied in depth - 5 follicle
centre cell lymphomas, 2 B cell small lymphocytic lymphomas, 1
splenic marginal zone lymphoma with areas of transformation to
diffuse large B cell lymphoma.
The lymphomas were grown for 20-23 days
immunophenotyping, growth fraction, cell numbers,
cytocentrifugation specimens for morphology were carried out at
regular intervals. For analysis results were spilt between the
follicle centre lymphomas and the non-follicle centre cell
lymphomas. Growth fractions were separated between those
lymphomas which showed evidence of transformation to high
grade histology on biopsy prior to culture and those that did not.
The results from lymphomas grown in the IL4/anti-CD40 system
were taken from samples that had their T cell and IgD bearing B
cells removed, however when compared to those which did not;
no substantial difference in GF could be determined.
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5.2 Immunophenotvping
Table 1: Immunophenotyping of cells
IMMUNOPHENOTYPING OF CELLS
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CD3 FITC
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• • • • •
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5.3 Histology (see Prints 1-81 - in 1L3/1L10 anti-CD40 system
Cytospins were examined at days 15 and 23 and compared to
touch imprints made of the original biopsies. (See Table 2).
Follicle Centre Lymphomas (L2. L5. L10.112)
Three of the follicle centre lymphomas maintained their parent
morphology with relatively plentiful centrocytes and rare
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centroblasts. Tumour cells were often adherent to the mouse
fibroblasts. 2 cases showed an overgrowth of large nucleolated
blast cells. 1 of these cases had plentiful blasts on the parent
imprint while the other case had an initial morphology
indistinguishable from the 3 non-transformed cases. By day 23
there was relatively plentiful cell debris and cells showed
progressive cytoplasmic vacuolation in culture.
Small lymphocytic and splenic marginal zone lymphomas (L3. L6.
L9)
Cells from the L3 case of B-small cell lymphocytic lymphoma
retained the morphology of small lymphocytes throughout the
culture period. The splenic marginal zone lymphoma which had
immunoblasts (transformed component) on a back round of
lymphoplasmacytoid cells - maintained this composite pattern.
Culture L9 - a small B cell lymphocytic lymphoma with
lymphoplasmacytoid differentiation continued to maintain these
cells in culture.
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Table 2: Morphology of cultured cells
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Prints 1-2: Touch imprints and cytocentrifugation specimens of
low grade B cell lymphomas studied
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Prints 3-4: Touch imprints and cytocentrifugation specimens of




Prints 5-6: Touch imprints and cytocentrifugation specimens of
low grade B cell lymphomas studied
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Prints 7 - 8: Touch imprints and cytocentrifugation specimens of
low grade B cell lymphomas studied
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LEGENDS TO PRINTS
Print 1: Touch preparation of original node biopsy, case L3,
lymphocytic lymphoma. Lymphocytes with coarse, clumped
chromatin are seen. MGGxIOOO.
Print 2: Case L3 cytospun cultures at day 10. Lymphocytes with
clumped chromatin are seen with scattered fibroblasts. Note
the increase in cytoplasm and cytoplasmic vacuolation
compared to Figure 5. MGG x 1000.
Print 3: Touch preparation of original node biopsy, case L5, follicular
lymphoma. The tumour is mostly composed of centrocytes
with occasional nucleolated centroblasts. MGG x 1000.
Print 4: Case L5 cytospun cultures at day 15. Centrocytes with
vacuolated cytoplasm are seen tightly clustered around a
mouse fibroblast. MGG x 1000.
Print 5: Touch preparation from original node biopsy, case L6,
lymphoplasmacytoid lymphoma with a high blast content.
Note the polymorphic mixture of large nucleolated blasts,
lymphoplasmacytoid cells and intermediate sized lymphocytes
with irregular shaped nuclei. MGG x 1000.
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Print 6: L6 cytospun cultures at day 16. Hyperchromatic, polymorphic
lymphocytes are seen adherent to the mouse fibroblasts. Note
the preservation of the range of cytological types seen in
Figure 1. MGG x 1000.
Print 7: Growth L12 - Touch . Follicle centre lymphoma with excess
blasts (grade 3).
Print 8: L12 day 16 - cytospun culture - mostly centrocytes showing
some degree of vacuolar with adherent fibroblasts.
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5.4 T cell and monocyte growth in the IL3/1L10 anti-CD40 culture
system (Tables 3 and 4)
The percentage of T cells and monocytes remained reasonably
constant during the 23 day study period. In the 8 lymphoma
specimens studied the mean percentage of T cells (CD3 positive)
on day 1 was 33% (SD 24.6) by day 15 this was 35% and fell to
18% (SD 14.2) by day 23.
The wide range was maintained during culture with a gradual loss
of T cells after 15 days. The number of monocytes (CD14
positive) was consistently low - mean 5% (SD 2.7) with a gradual
increase to 9% (SD 2.6) by day 23. These were not analysed in
the IL4/anti-CD40 system.
Table 3: Table showing CD3% Expression with time
Lymphoma Histology Day 1 Day 5 Day 10 Day 15 Day 23
L2 FCL 38 74 67 58 39
L3 SLL 12 11 6 22 11
L5 FCL 28 9 12 35 11
L6 SMZL7DLBCL 88 75 46 62 19
L9 SLL 14 24 13 12 9
L10 FCL 8 11 10 28 1
L11 FCL 26 25 30 23 12
L12 FCL 50 33 35 40 44
Tonsil 35 13 13 12 19
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Table 4: Table showing CD14% Expression with time
Lymphoma Histology Day 1 Day 10 Day 23
L2 FCL 5 16 13
L3 SLL 2 2 6
L5 FCL 2 9 7
L6 SMZL/DLBCL 7 12 8
L9 SLL 4 3 12
L10 FCL 4 5 12
L11 FCL 11 5 7
L12 FCL 5 9 7
Tonsil 9 2 3
5.5 Growth fraction of cultured lymphomas (see Figure 1. p.921
Results are grouped according to whether there was
morphological evidence of blastic transformation (on the histology)
or not. Transformation was seen in 1 follicle lymphoma and 1
splenic marginal zone B-cell lymphoma. Results were compared
to those seen on day 10 in the same lymphomas grown in
IL4/anti-CD40. 1 follicle centre lymphoma grade 1, underwent
blastic transformation in culture (L2). This was seen on repeated
culture attempts.
(a) IL3/IL10/anti-CD40
(i) No evidence of transformation - Growth Fraction (GF) on
day 1 (mean of 6) was 7.5% (standard deviation, SD 4.9).
This was stable for the first 10 days (mean 6.5%), (SD 5.1)
rising to a mean of 14.1% thereafter (SD 5.8).
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(ii) Transformed (mean of 2 cases) - These had a higher initial
growth rate (mean 12.0%, SD 2.0 on day 1), falling to
7.2%, (SD 0.8) by day 10 and subsequently increasing to
22.5% by day 23 (SD 4.5).
(b) IL4/anti-CD40
(i) No evidence of transformation:- the GF on day 1
remained the same at 7.5% (SD 4.9) (mean of 6 cases) but
by day 10 it had risen to 21.7% (SD 8.8).
(ii) Transformed:- the initial growth rate of 12.0% (SD 2.0)
(mean of 2 cases) rose by day 10 to 28.3% (SD 4.8).
5.5.1 Cell Number (see Figure 2, p.93)
The cell count rose slowly using IL3/IL10/anti-CD40 with an
approximate 2 fold expansion over 3 weeks in those showing no
evidence of transformation compared with a 5 fold expansion in
those showing transformation. In 4 cases on day 23 when the
cells appeared to stop growing, IL4 was added to the culture
system to stimulate further growth (L2, L6, L5, L11). This was not
effective.
5.6 Establishing a Monoclonal Expansion (see Table 51
2 colour staining revealed light chain restriction in all 8 cases prior
to culture. In the IL3/IL10 anti-CD40 system, light chain restriction
could be demonstrated in all at day 10. The corresponding results
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in the IL4 T cell/lgD bearing cell depleted population showed a
large degree of concordance. There was no evidence at this
stage of any reduction in monoclonality. At day 23, it could be
seen in 4. Expression of light chains was too poor to analyse in
the other 4, and in 3 of these cases there was evidence of blastic
transformation on cytocentrifugation specimens at this time.
Table 5: Table showing Light Chain Restriction at Day 10 in cultured
samplescomparing growth in IL3/IL10 (no T cell depletion) versus that
in IL4 (T cell and IgD bearing cells depleted)
Lymphoma Histology Day 1 IL3/IL10 IL4
Day 10 Day 10
L2 FCL 100%X 93%X. 95%X
L3 SLL 99%X 99%X 99%X
L5 FCL 99%\ 82%X Poor Expression
L6 SMZL/DLBCL 96%X 90%X Poor Expression
L9 SLL 99%X 98%X 98%X
L10 FCL 97%X 95%X 78%X
L11 FCL 97%X 95%X 75%X
L12 FCL 90%X 88%X 61%X
Tonsil K + X K+X K + X
5.7 B Cell Phenotvpe during Cell Culture
(a) CD38 (see Figure 3, p.94 and Table 6)
3 groups were studied: a) follicle centre lymphoma, grown
in IL4/anti-CD40 (2 samples); b) follicle centre lymphoma,
grown in IL3/IL10/anti-CD40 (5 samples); c) non-follicle
centre lymphomas grown in IL3/IL10/anti-CD40 (3 samples.
Initial mean expression of CD38 in the follicle and non-
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follicle centre groups was 46% (SD 10.7) and 30% (SD
17.6) respectively. Those grown in the IL3/IL10 system
maintained CD38 expression at over 50% of original at day
5 and 20% of original at day 10 with an increase to over
35% by day 15. The lymphomas grown in IL4 lost almost
all CD38 +ve cells within 5 days with no evidence of
regrowth. The maintenance was not due to staining of T
cells as these remained in all the groups and 2 colour
staining CD3 PE/CD38 FITC failed to show more than 5%
of cells coexpressing both.
Table 6: Table showing CD38 % expression with Time.
Lymphoma Histology Day 1 Day 5 Day 10 Day 15 Day 23
L2 FL 56 28 27 46 18
L3 SL 31 13 2 8 8
L5 FL 34 27 19 24 7
L6 LPC 51 35 21 29 17
L9 LPC 8 8 2 2 1
L10 FL 65 16 3 2 1
L11 FL 59 31 4 2 2
L12 FL 60 38 7 25 21
(b) CD19 (see Figure 4, p.95 and Tables 7a and 7b)
The follicle centre lymphomas were grown in IL3/IL10/anti-
CD40 (5 lymphomas) or in IL4/anti-CD40 (2 lymphomas)
and the non follicle centre lymphomas (3 samples) were
only grown in IL3/IL10 anti-CD40. Mean expression was
35% (SD 14.1), 23% (SD 5.0) and 54% (SD 27.7)
respectively. IL4 was the greatest promoter of CD19 cells
83
initially. The IL3/IL10 groups showed a small smaller
variation compared to the original samples than the IL4.
There was loss of CD19+ve cells in all cultures by day 23 -
the levels being stable for the first 15 days (see Tables 7a
and 7b).
Table 7a: Table showing CD19 % Expression with Time in IL3/IL10.
Lymphoma Histology Day 1 Day 5 Day 10 Day 15 Day 23
L2 FCL 34 24 30 34 24
L3 SLL 89 91 92 87 63
L5 FCL 18 60 46 61 20
LG SMZL7DLBCL 21 16 42 88 13
L9 LPC 53 80 59 35 2
L10 FL 57 91 32 16 8
L11 FL 44 63 46 22 3
L12 FL 23 40 15 12 11
Tonsil 67 75 45 66 47
Table 7b: Table showing CD19 % Expression with Time in IL4.
Lymphoma Histology Day 1 Day 10 Day 24 Day 36
L2 FCL 27 68 60 3
L12 FCL 62 53 32 0
(c) CD10 (see Figure 5, p.96 and Tables 8a and 8b)
Only follicular lymphomas expressed this. 5 were grown in
IL3/IL10/ anti-CD40; 2 in IL4/anti-CD40. Mean expression
was 46% (SD 21.6) (IL3/IL10) and 18% (SD 14.0) in (IL4)
compared to original expression. Both groups followed a
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similar pattern involving first the loss of CD10 bearing cells
followed by an increase in their number peaking on day 10
in the IL4 system and day 15 in IL3/IL10.
Table 8a: Table showing CD10 % Expression with Time.
Lymphoma Histology Day 1 Day 5 Day 10 Day 15 Day 23
L2 FCL 30 20 20 31 14
L3 SLL 1 2 2 10 8
L5 FCL 32 45 29 37 10
L6 SMZL/DLBCL 2 18 10 25 12
L9 SLL 2 7 8 7 16
L10 FCL 86 70 12 2 17
L11 FCL 51 41 12 16 28
L12 FCL 30 44 6 N/A 12
Tonsil 14 3 3 5 6
Table 8b: Table showing CD10 Expression in IL4
Lymphoma Histology Day 1 Day 10 Day 24 Day 36
L2 FCL 46 46 17 9
L12 FCL 30 6 4
(d) CD22 (see Figure 6, p.97 and Table 9)
This was analysed in 5 follicle centre lymphomas and 3 non
follicle centre grown in IL3/IL10 only. Expression was
initially 52% (SD 15.7) and 20% (SD 4.9) respectively. A
gradual loss of expression was seen in the follicle centre
lymphomas whilst the non follicle centre ones decreased
expression gradually.
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Table 9: Table showing CD22 % Expression with Time In IL3/IL10
Lymphoma Histology Day 1 Day 5 Day 10 Day 15 Day 23
L2 FCL 53 29 34 45 41
L3 SLL 19 19 14 14 8
L5 FCL 34 37 35 48 16
L6 SMZL/DLBCL 14 20 46 60 28
L9 SLL 26 43 21 18 9
L10 FCL 69 78 28 12 18
L11 FCL 69 52 46 36 19
L12 FCL 34 52 28 33 35
Tonsil 59 69 39 61 44
(e) CD34
No cells bearing this phenotype were detectable using flow
cytometry.
5.8 Bcl-2 Production (see Figure 7. p.98 and Table 10 for Individual
Results)
Bcl-2 protein was measured in growing and resting cells (the cells
were separated by PI binding) in IL3/IL10 and IL4. Percentages
are quoted versus a negative control.
a) IL3/IL10
One lymphoma - (L3) did not express bcl-2, initially,
however, after 10 days in culture 93% of cells expressed
it. The follicle centre lymphomas expressed it quite
strongly at first (mean 59% ± SD35) whilst the non-follicle
centre ones expressed it to a lesser degree (mean 31%
SD40).
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Expression in the follicle centre group remained stable
falling at the end of culture whilst in the non follicle centre
group expression was upregulated. In both groups there
was a tendency for resting cells in culture to express bcl-2
more strongly than the growing cells during in vitro
culture, at variance with the initial finding.
b) ]L4
Expression was assessed at day 10. Overall, the
tumours had a high level of expression, however, the
small lymphocytic lymphoma failed to upregulate bcl-2 in
this system to the same degree as in IL3 + IL10
suggesting that the choice of cytokine might have
different effects on different lymphomas.
Table 10: Table showing bcl-2 expression with time in growing and resting cells




Growing Resting Growing Resting Growing Resting
L2 FL 100 91 36 38 79 90
L3 SL 0 0 93 93 9 28
L5 FL 11 8 20 53 27 33
L6 LPC 5 14 9 16 30 59
L9 LPC 92 86 67 97 100 100
L10 FL 59 25 82 79 100 100
L11 FL 30 21 63 47 100 100
L12 FL 97 91 71 71 10 20
87
Discussion
The IL3/10 anti-CD40 stromal cell culture system provides an
improved model for studying low grade lymphoma growth. Unlike
its predecessors it produces a low growth fraction throughout the
period studied. It supports follicle centre and non follicle centre B
cell lymphomas equally well and morphology correlates well with
the original lymphoma. The demonstration that no prior T cell
depletion is required is a useful finding in that it simplifies the
culture system. It may be that various T cell derived cytokines
and adhesion molecules are critical in the maintenance of B cell
morphology.
The ability to freeze and then resuspend the lymphoma cell
suspensions without substantial loss of viability greatly enhances
the flexibility of the system and allows direct comparison of
lymphomas taken at various stages of their history. Proof of
monoclonal expansion comes from light chain restriction studies.
These confirmed that despite the fact that there was no T or IgD
bearing cell depletion, there was no suggestion that the cells in
this system were less likely to show restriction than those in IL4.
Cytogenetic analysis was not undertaken in part because of the
slow growth rate made colcemid treatment difficult to time and
also because of the limited number of cells - particularly in the first
5-10 days. The morphological variations between the tumours -
and the retention of parent tumour morphology seen on
cytocentrifugation specimens is further evidence that what was
growing did not represent a benign reactive B cell population as
this would be expected to look similar in all cases studied.
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The model appears to support 3 phases of cell growth and
development as assessed by FACS analysis. During the first 10
days, there is a gradual loss of mature (CD38+ve) cells and a
relatively low growth fraction. The total number of cells may
actually fall during this time (see Figure 9). For the next 5-7 days,
as cells which are proliferating start to mature, the percentage of
more mature cells increases again. In the last stage, although
cells are still dividing it appears that they fail to mature beyond 23-
25 days. This may represent a failure to recruit newly divided
cells into the maturation pathway.
In 4 lymphomas at day 23, the addition of IL4 failed to induce
further proliferation or maturation and there is no suggestion of a
CD34+ve cell pool which replenishes the system. The length of
time this culture system can continue for is less than that
described for IL4/anti-CD4034, as the cells do not respond to IL4
at this stage, whilst when all 3 cytokines are combined initially
(data not shown) there is no evidence of antagonism (although
CD38+ve cells are rapidly lost). It must therefore be concluded
that at least part of the IL4 sensitive sub-population is not
supported by IL3/IL10. Unfortunately although IL4 driven B
lymphoma cells will proliferate for longer this is at the expense of
loss of B cell phenotype as judged by CD19 and CD22
expression.
The role of the stromal cells in such a culture system is complex.
Neither IL3 alone, nor IL3 in combination with soluble anti-CD40,
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lead to B cell proliferation. Whilst similar concentrations combined
with stromal cells do cause B cells to divide71 indeed short term
culture of follicular lymphoma cells in vitro appears to be inhibited
by IL3 - at least for 72 hours45. The stromal cells were stained
with anti follicular dendritic cell antibody (DRC-1) to ascertain if
they fulfilled this role, however, they were negative for this as well
as the adhesion molecules CD11a and CD54. They stained
weakly for CD58 suggesting that these adhesion molecules could
not provide the necessary B cell ligands which the normal stromal
cells did.
Bcl-2 expression was maintained until the end of the time period
studied when its reduction correlated with the increasing number
of vacuolated cells which were presumably losing viability. Initially
expression was higher in growing than resting cells but with time
this was reversed. Cytokines have been shown directly to
influence bcl-2 expression as does cross linking of CD40. IL4
suppresses apoptosis in B-CLL by maintaining bcl-2 levels50, anti-
CD40 does the same30 and in germinal centre cells increases bcl-
2 expression. As constitutive bcl-2 expression is not sufficient to
prevent apoptosis presumably anti-CD40 works through other
mechanisms as well. In particular, many growing cells did not
express bcl-2 in culture.
It is interesting that the non follicle centre lymphomas originally
expressed bcl-2 to a lesser extent than the follicle centre
lymphomas, but by day 10 expression was equivalent. This was
most marked in the small lymphocytic lymphoma which did not
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express bcl-2 at all initially; presumably the IL3/IL10 and anti-
CD^ was affecting expansion directly regardless of initial levels.
The prolongation of the presence of germinal centre cell
equivalents (CD19+ve, CD38+ve) although much greater in
IL3/IL10 as opposed to IL4 alone was also seen in cells cultured
in IL3/anti-CD40. The cells strongly expressed bcl-2 which
suggests that IL10 may not be critical to their survival58, that IL4
was unable to do this despite bcl-2 upregulation (data not shown)
again brings the central role of bcl-2 into doubt.
Recently, it has been shown that c-myc which normally induces
proliferation can induce apoptosis in serum deprived fibroblasts in
the presence of various cytokines. Such an effect can be
nullified72 in the absence of growth promotion. Furthermore, it
appears that the presence of p53 may be required to convert the
proliferative signal into an apoptotic one73. In a similar way, it
may be that the balance between bcl-2 and its partner bax which
induces apoptosis74, is modulated by the cytokines IL3 and/or
IL10 and/or anti-CD40 so that the absolute level of bcl-2 may
become irrelevant. Further investigation into the balance between
bax and its candidate partners may be helpful in this system.
In summary, a modified culture system for low grade B cell
lymphoma is described which maintains many of the in vivo
morphological and growth characteristics for 20-25 days and may
permit the in vitro investigation of drug sensitivity and mechanisms
of drug resistance as well as the assessment of biological therapy.
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6. CULTURING HODGKIN'S LYMPHOMA
6.1 Introduction
The difficulty in studying this disease has required several
methods of investigation to confirm the growth of the putative
malignant cells in vitro. This chapter describes the use of these
methods to establish the nature of the cells growing in culture.
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6.2 Rationale for the IL3/1L10 anti-CD40 stromal cell system
Hodgkin's lymphoma has proved very difficult to study in-vitro.
The putative malignant cell, the Reed-Sternberg-Hodgkin cell (RS-
H) has proved resistant to in-vitro expansion and makes up a
small proportion of cells within the affected lymph node75'76. The
origin of the cell is unknown but a B or T cell origin is probable70.
T and B cell markers are variably expressed although most LP-HL
express CD2070 (a B cell marker) and k or X light chain mRNA
has been found in 50% of LP-HL suggesting a B cell origin for this
subtype at least. EBV has long been linked to HL and 50% of
cases express EBV latent membrane protein70. Its ability to
induce the proliferation of infected B lymphocytes appears to
require the production of hlL1055. RS-H cells have been shown to
express CD40, but binding to its natural ligand (CD40L) mitotic
activity did not occur in HL derived cell lines37. However, LMP-1
may upregulate CD40 in RS-H cells and this may represent a
mechanism for EBV induced RS-H growth77.
As there was now evidence that the IL3/IL10 anti-CD40 stromal
cell system was able to maintain morphological and
immunophenotypical features of the various low grade B cell
lymphomas, the clear B cell characteristics of LP-HL, the
possession of CD40 by RS-H cells, and the link between the EBV
infection and hlL10 synthesis made the system attractive to study
in HL.
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Lymph nodes from patients with HL were taken, T cell depletion
was carried out if the CD3 proportion exceeded 60%, and the
remaining cells were cultured in the stromal cell system.
Phenotyping for CD15 and CD30, DNA profiles using FACS
analysis, light microscopy features on cytocentrifuged specimens
were carried out. Clonality of the cultured cells was sought using
conventional cytogenetic karyotyping in four cases as well as PCR
analysis for IgH rearrangements on cells at various times in
culture. Where numbers allowed CD30 expression based cell
sorts were carried out using flow cytometry to compare the CD30-
ve and CD30+ve populations.
Lymphoma characteristics at biopsy
The histology, EBV status and T cell portions as assessed by CD3
staining using flow cytometry is shown in Table 1 and the clinical
status of the patients with regards to stage and number of
previous relapses is shown in Table 2. 2/6 cases were EBV




Lymphoma Histology EBV Status CD3% T Cell
Depletion
L17 LP -ve 78 Yes
L18 MC -ve 78 Yes
L20 LP -ve 36 No
L25 MC +ve 82 Yes
L27 NS -ve 40 No
L28 NS +ve 85 No





L20 1st Relapse 1Mb (Restaqed)
L25 Presentation lla
L27 2nd Relapse lllax (Restaqed)
L28 6th Relapse IVa (Restaqed)
6.4 Light Microscopy of Cvtocentrifuaation Specimens (see Table 3)
The cases were studied at 3 points during culture. Photographs
of selected cases (prints 1-5) with the benign control given for
comparison. In 3 cases cell sorting allowed direct visualisation of
the CD30 positive and negative cells. The CD30 negative sorts
generally contained fibroblasts and vacuolated lymphoid blasts,
whilst the CD30 positive sorts contained the bi and multinucleated
cells.
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LEGEND FOR PRINTS - HODGKIN'S LYMPHOMA
Print 1: L25-Day14
CD30+ve cell sort - showing mitotic cells.
Print 2: L25-Day14
CD30+ve cell sort - classical Reed-Sternberg cell.
Print 3: L25-Day14
CD30-ve cell sort - showing mouse fibroblasts and small
mononuclear cells.
Print 4: L18 - Day 15
Mononuclear blast cells with occasional multinucleated cells.
Some cells show plasma cytoid features.
Print 5: L20 - Day 9
Large mononuclear cells interspaced with small lymphocytes.
Some multinucleated and bilobar cells.
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6.5 CD15 and CD30 expression during culture - bv FACS analysis
(see Table 4 and Figures 1 - 3)
Upregulation of CD15 and CD30 were seen in all lymphoma
cases although often the values were not identical. Overall, CD30
seemed to be more strongly expressed than CD15. In the
reactive control (R1) no such upregulation occurred. In most
cases this peaked at between day 10-19.
Table 4
Lymphoma Day 1 Day 5-9 Day 10-19 >Day 20
CD15 CD30 CD15 CD30 CD15 CD15 CD15 CD30
L17 18 14 44 33 46 41 66 92
L18 9 1 18 24 33 57 19 26
L20 11 4 14 18 50 83 38 20
L25 6 3 - - 63 76 - -
L27 6 4 - - 20 25 - -
L28 15 33 33 35 54 50 85 72
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Figure 1: FACS analysis showing histograms of CD15 and CD30
expression in Hodgkin's lymphoma pre and post culture
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Figure 2: FACS analysis showing histograms of CD15 and CD30


























Figure 3: FACS analysis showing histograms of CD15 and CD30
expression in Hodgkin's lymphoma pre and post culture
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6.6.1 Light Chain Expression
Only L17 (k) and L20 (X) (LP-HL) expressed light chains. In both
cases using 2-colour FACS analysis, the original light chain
restricted persisted in culture.
6.6.2 CD 19 and CD22 Expression
Both the lymphocyte predominant tumours expressed B cell
markers CD19 and CD22 by FACS. These were maintained
during culture. In other tumours (L18, 25 and 28) CD19
expression remained at a low level and may have represented
benign B cells.
6.7 Growth Fraction in vitro (see Tables 5 and 6 and Figures 4 and 51
This was measured using either PI or Hoechst uptake. In L17,
L20 and L25 sufficient number of cells were available to allow
sorting into CD30+ve and CD30-ve populations. When separated
into positive and negative cells; the +ve population always seen
have the higher growth fraction. The percentage represented the
cells that were not diploid.
Table 5
Growth Fraction Day 1 Day 5-9 Day 10-19 >Day 20
L17 6 19 13 18
L18 - 20 15 1
L20 9 35 15 14
L25 - - 38 -
L27 - - 26 -
L28 12 36 37 -
Reactive Control 13 38 23 25
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Figures 4 - 5: FACS analysis of two cases of Hodgkin's lymphoma






Sorted Cells - Cells sorted on Day 15
CD30-ve CD30+ve
M1 M2 M3 M1 M2 M3
L17 69 5 1 69 10 2
L20 81 4 0 61 11 1




Cytogenetics (see Table 6)
4 out of the 6 samples were evaluated by conventional
karyotyping. Although abnormalities were seen in culture, no
clonal changes were seen and no consistent abnormalities could














4 Hyperdiploid Cells - Probably Tetraploid
1 46,XX,del(1)(q?q?)
27 - Normal Karyotype
L20
(LP)
30 Cells Fully Analysed
15 Further Cells Checked for del(20)(q)
1/45 del(20)(q)








Samples were considered to be +ve when a single band was
detected on electrophoresis - see Table 8.
Table 8: Results of the PCR analysis for the detection of clonal IgH Rearrangement
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The primary culture of HL from cells obtained at biopsy has been
demonstrated using the IL3/IL10 anti-CD40 stromal cell system.
Compared to the pattern seen with low grade B cell NHL, the
growth fraction seemed to be much higher than the in-vitro rate as
studied using PI. The fact that the CD30+ve population had a
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higher growth fraction than the CD30-ve population suggests
these cells to be actively dividing rather than CD30 being acquired
as a maturation effect. The cytokines and stroma presumably
antagonised the effect of CD40 ligation to down regulate CD30
expression37. In the reactive controls, little upregulation of CD15
and CD30 occurred, discounting the suggestion that the major
upregulation might just be a culture artefact. However, it was
consistent with the findings of Stein et al77 that some CD30
upregulation follows activation of lymphocytes.
Unfortunately, PI and Hoechst 3342 cannot differentiate between
resting and tetraploid cells and dividing diploid ones. However,
the presence of small numbers of cells in the M3 band of
hypertetraploid cells suggested that the hyperdiploid cells might
be dividing as well. It was of note that the growth kinetics and
expression of CD15 and CD30 appeared similar in the LP - and
the non LP subtypes and it was only the lack of obvious light chain
restriction which separated those subtypes. This represents
supporting evidence that these diseases are correctly grouped
together6, and that LP-HC may simply have a more committed B-
cell differentiation.
The lack of clonal cytogenetic abnormalities was seen in the
sorted (CD30+ve) and non sorted specimens on repeated culture
attempts. No consistent cytogenetic abnormalities have been
found in HL70 and the presence of Ig rearrangements could be too
subtle to be recognised by conventional karyotyping techniques.
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Occasional tetraploid cells were seen, although the quality of
these was often too poor for full analysis.
In studies of uncultured HL, cytogenetic analyses have been
complicated by the fact that so few cells are dividing. In LP-HL
most mitoses have proved to be normal78. In Rowley's series of
HL only 4/25 yielded clones78 and these could not be completely
karyotyped. Most recent series have yielded conflicting data.
Schlegelberger et al69 studied 21 patients using combined
immunophenotyping and karyotyping and found aberrant clones in
12 - all in CD15/CD30 bearing cells. Most of these were complex
abnormalities, 2 appeared to involve only the sex chromosomes.
In contrast Ladanyi et al79 in the largest series to date of 95 cases
found that 81% had normal karyotypes and of the 19% which
should any karyotypic abnormalities 3/i3 were non clonal; thus
results from cytogenetic investigations are variable.
Specific translocations have not been linked to HL and although
bcl-2 protein is produced by the RS-H cells attempts to link bcl-2
production to the t(14;18) has been disappointing80 and there is
some doubt as to whether t(14;18) bearing cells when found are
actually malignant81.
The Ig heavy chain rearrangements were found in most cases
studied. Although confined to the CD30+ve population (L25, L17)
they were seen in both in one case (L20), the sensitivity of the test
and the known failure rate of the sorting procedure would be able
to account for this. The presence of these and the ability to grow
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the lymphoma in a B cell culture system support a B cell origin for
this disease.
Molecular techniques using Southern blotting to analyse the
configuration of Ig and T cell receptor (TCR) rearrangements have
produced heterogeneous results ranging from absence in the
majority of studies to clonal rearrangements in some23'82"87. This
may, however, represent the paucity of tumour cells. In addition,
the distinction between a DJ and VDJ rearrangement can not be
made because of the use of Jh probes. Another disadvantage of
using Southern blots is that relatively large amounts of
undegraded DNA are required. A PCR based technique
overcame this problem and was able to detect only a VDJ
rearrangement that was lineage specific and enabled the clonality
rearranged Vh genes to be sequenced allowing detection of
somatic mutations in the V regions, thus permitting the distinction
between pregerminal (naive) or post germinal (memory and
effector B cells).
Recently, microdissection of sections of HL and the taking of
individual RS-H cells characterised by their expression of CD15
and CD30 with the use of a PCR based technique to amplify the
Vh region has revealed that cells in a particular patient come from
a single clone (3 patients studied)88. This may be because of a
selective growth advantage of the malignant cells. However, in all
cases studied a band was present prior to culture suggesting the
method to be sufficiently sensitive to pick low levels of clonal
populations. The ability of the molecular technique used to
120
identify a band in most cases studied contrasts with the inability of
others89 to find such evidence when looking at uncultured
samples.
In the absence, of microdissection, using a PCR based technique
to study Ig rearrangements in paraffin embedded samples only
1/36 showed Ig rearrangement89. Confirmation of the clonal
nature of RS cells has been carried out using chromosome
specific and satellite DNA probes from different biopsies of the
same patients. Interestingly, 20% in the RS cells showed diploidy
whilst the rest were aneuploid or tetraploid74.
The failure to find karyotypic evidence of a specific translocation
associated with any subtype of HL has encouraged the use of a
PCR based strategy to look for the t(2;5) - found in some cases of
anaplastic large cell lymphomas90. In one series this was found in
11/13 NS cases studied91, although it has not been confirmed by
others92.
Cytocentrifugation specimen analysis was crucial to the
interpretation of the findings. It confirmed the success of the cell
sorting using CD30. The presence of RS cells and mononuclear
H cells and the ability of the LP subtypes to differ in culture from
the others in terms of the relative frequency of these cells and the
large numbers of blast-like cells confirmed the difference in culture
between LP and non LP subtypes. The number of RS type cells
in culture was similar to the proportion seen in vivo - in a lymph
node with HL and much lower than that suggested by the
121
proportion of CD15 and CD30. L18 (MC) was unusual in that
although binucleated cells were present in culture, the majority of
cells were plasmacytoid as the culture progressed, a finding not
seen in other cases. L20 represented an unusual case in that the
patient relapsed with LP-HL 22 years ago and the relapse
specimen at the time of biopsy showed sheets of L+H cells
representing clonal progression to high grade B cell lymphoma.
The presence of light chain restriction in culture with the
persistence of the Ig heavy chain clone supports the fact that this
is one disease.
The participation of T cells in the growth of HL as opposed to
them being 'bystanders' or indeed fighting the disease is
suggested by the fact that the CD30 ligand (CD30L) is present on
T cells and the binding24 to CD30 leads to differentiation and
proliferation of CD30 bearing cells. This has been seen in HL and
cell lines with T cell phenotype and may be a good argument not
to T cell deplete prior to culture. Indeed, the one case where T
cell depletion was not carried out because of the poor viability of
the cells (L28) was able to proliferate very well without evidence of
T cell overgrowth.
The number of tumours judged to be EBV positive by LMP status
is in keeping with general findings - in particular both LP cases
were LMP-ve. The suggestion that primary culture of Hodgkin's
lymphoma of a variety of subtypes both EBV positive and negative
is indeed possible using this system can be inferred from the total
evidence presented. The strongest comes from FACS analysis
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and cytocentrifugation specimens. Whilst FACS gives quantitative
information on the percentage of CD15-ve and CD30+ve cells
cytocentrifuged slides can confirm the presence of RS/L+H cells.
It is of course not possible to say whether the bands obtained by
PCR are from these cells but the fact that they were not present in
benign tissue cultured, supports the fact that they came from the
malignant clone(s).
In summary, the IL3/IL10 stromal cell system appears to support
the growth of Hodgkin's lymphoma of both LP and non LP
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7. THE CD80 ANTIGEN AND ITS APPLICATION TO
IMMUNOTHERAPY
7.1 Introduction
The CD80 antigen (B7-1) is one of a recently recognised group of
accessory antigens which are considered to be very important in
the eliciting of a T cell immune response. This chapter reviews
the role of CD80 in immune regulation and describes the
prevalence of CD80 expression in low grade B cell lymphoma as
assessed by flow cytometry. Induction of CD80 expression in the
stromal cell culture system is carried out using IL4 and
comparisons with the results using IL3/IL10 are made.
Assessment of these cells' immunogenicity by a primary mixed
lymphocyte reaction is described and the results of autologous
and allogeneic T cell responses are presented.
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CD80 and Immune Function
The CD80 antigen93, previously called B7, was first described in
1987 by Freedman et al94. Then it was considered to be B cell
restricted and initial work suggested that it appeared in B cells
within 24hrs of in vitro activation. It was found in a subset of B
lymphocytes but not in T cells or monocytes - in addition it was not
detected in leukaemia or lymphomas of T cell origin. It was found
in some B-CLL, and prolymphocytic leukaemia as well as diffuse
histiocytic lymphomas, but not in myeloma. Several cell lines
expressed it - including Raji, Daudi and Ramos.
The antigen is a member of the immunoglobulin (Ig) superfamily95
- a type 1 protein - 262 amino acids long with extracellular
transmembrane and intracellular regions. The extracellular region
contains two Ig domains - the first resembling the variable region
and the second the constant domain. The gene encoding CD80
has been mapped to chromosome 3q13-q2396. The original
ligand described for CD80 was CD2897-98 and this is present on T
cells and mediates adhesion with B cells by interacting with
CD8098. The binding leads to IL2 synthesis by the T cells94. It
was subsequently found by Linsley et al in 1991 that another
receptor for CD80 existed, this was called CTLA4 and was
identified by screening a murine cytolytic T cell cDNA library100.
The gene for the human counterpart was cloned to the same
region as CD28 (2q33-34) and the proteins showed some
homology. Studies were undertaken using a fusion of the CTLA4
extracellular domain with an Ig Cy1 chain to make CTLA4 Ig.
CTLA4 Ig bound CD80 more avidly than CD28100. Studies
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looking at the inhibitory role of antibodies against CD80 and the
CTLA4 Ig found a difference in blocking ability - CTLA4 Ig -
completely blocked T cell proliferation mediated by CD80 whilst a
specific anti-CD80 antibody (B7-24)101 was unable to do this.
This suggested that more than one ligand for CTLA4 existed.
A second ligand was subsequently found termed B7-2102 by one
group and B-70 by another103 - it was found to be the same as
CD86104. This is a 70kd protein and there was evidence that it
was also a member of the immunoglobulin superfamily which was
found on resting monocytes, dendritic cells and on activated T, NK
and B lymphocytes103. The gene mapped to the same region as
CD8096. CTLA4 bound to CD86 as well. Upregulation occurred
within 24hrs105, compared to CD80 which took 48-72hrs. A 3rd
molecule B7-3 has more recently been identified106. This
upregulated over the 48-72hr period and was recognised by BB-1
- the original antibody106 which recognised CD80. This may have
lead to differences in staining patterns when this antibody was
used95, other antibodies producing different results. One, MAb
104 recognised CD80 on B cells and also on transformed T cell
lymphomas as well as 3/5 CLL, 5/5 follicle centre lymphomas
(FCL)107. Another, B7-24101 which recognised CD80 has been
shown to block mixed lymphocytes reactions with T cells.
Although not initially found on resting monocytes - activated ones
have been found to express CD8054 and suppression of
macrophage activation by IL10 appears to act by downregulation
of CD8054. It has also been found in Reed Sternberg cells108'100
where it is thought to be important in T cell stimulation and
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induction of cytokine synthesis and suggest that T cell may be
actively involved in Hodgkin's lymphoma rather than bystanders.
The most potent suppressor of T/B cell responses affecting the B7
system is CTLA4 Ig as the affinity of CTLA4 is for all members of
the B7 family.
The interaction between CD40, CD80/CD86 and CTLA4/CD28 is
complex. CD40 on B cells, binding to the CD40L on T cells
stimulates CTLA4 production as well as CD28 - and this induces
CD80/CD86 on the B cells. This leads to IL4 production by the B
cells which upregulates CD80 expression28. In addition, ligation
of CD80 with CD28/CD86 leads to CD40L expression and the
synthesis of IL4110. IL2 also has been shown to upregulate
CD80111 (see Figures 1 and 2).
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Figure 1: Interaction between T and B cells showing how CD40 and IL4
mediate a positive feedback loop to induce CD80/CD86 expression
TCR - T cell receptor
MHC - Major histocompatibility complex
CD40L - CD40 ligand
IL4R - IL4 receptor
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Figure 2: The T/B/Macrophage interactions and their regulation by
cytokines and CD80 System
PROLIFERATION
This system of positive feedback in B lymphocytes was a rationale
for investigating CD80 expression in low grade B cell lymphomas
cultured on anti-CD40 stromal cell system.
Binding of CTLA4 and CD28 to CD80 is via the complementary
determinatory region (CDR1) and CDR3 analogous regions which
are conserved in both molecules104. Residues in the V domain of
CD80 have been implicated in the functional interactions with
CD28 and CTLA4. One such residue is conserved in CD86.
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Mutations in this domain lead to failure of upregulation of IL2
production by phytohaemagglutinin (PHA) stimulated Jurkat
cells112.
The role of CD80 and other adhesion molecules in B/T cell
interactions
For antigen to be presented successfully to T cells 3 signals are
required:- recognition, adhesion and costimulation (see Figure 3).
1) The antigen must be presented with Class I (for intracellular
protein) or Class II (Major Histocompatibility antigens) to the
T cell receptor/CD3 complex - coupled to Class I - a CD8
molecule is needed whilst coupled to Class II a CD4
molecule is required.
2) Adhesion: Several adhesion molecules are required:- the
antigen presenting cell possession LFA-1 (CDHa/18), CD54
(ICAM-1) and CD58 (LFA3) - the T cell has corresponding
counter ligands LFA-1 and CD54 make a pair as do CD58
and CD2 and CD106 (VCAM) and CD49 d/29 (VLA-4).
3) Costimulation: In addition an accessory signal is required
(costimulatory signal). Costimulating signals: CD58, CD54,




HLA - DR/DP/DQ CD3/TCR/CD4








CD80 CD28 or CTLA4
CD86 CD28 or CTLA4
Failure to deliver a costimulating signal leads to the T cell failing to
produce IL2 which can act in an auto/paracrine fashion to induce
T cell proliferation.
Some of the adhesion molecules listed can act as costimulating
ones - whilst CD54 can induce an allogeneic response, it can be
inhibited by cyclosporin and it fails to lead to IL2 synthesis - unlike
CD80113.
In addition - a rechallenge of T cells - leads to a secondary
response only with CD80. With CD54, anergy results which can
be overcome by the addition of exogenous IL2 suggesting that T
cells respond normally when correctly stimulated.
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The role of CD80 in tumour vaccines
The most exciting evidence for the crucial role of CD80 in the
production of tumour vaccines came from work by Townsend and
Allison114. In a murine model they grew a murine melanoma cell
line in athymic mice, this was then taken and transfected with
CD80. The cells were equally tumourigenic in athymic mice, but
in intact mice only the CD80 naive tumour grew aggressively with
most CD80 expressing tumours disappearing or becoming static.
Vaccination with fragments of CD80 expressing cells protected
most mice against challenge with CD80 naive tumour cells. T cell
depletion allowed CD80 expressing tumour to grow rapidly when
CD8 cells were depleted but not when CD4 cells were depleted.
Thus, providing costimulation by expression of CD80 protects
against subsequent challenge by CD80 naive cells and this is
mediated by CD8 T cells.
Cotransfection with CD80 and IL7 is able to induce CD28 and
CD25 (IL2 receptor) in T lymphocytes. In CD80 transfected
tumours only, the T cell response was mostly CD28+ve; CD25-ve;
whilst in IL7 transfectants it was the other way around suggesting
the two to be acting via different pathways112. In similar
experiments immunising mice with transfected cells and then
challenging with CD80/IL7 immune cells suggested that the
CD80/IL7 cells provided better protection than either on its own.
Abrogation by irradiation of the cells suggested that live tumour
cells would be required for such an approach112.
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7.5 Evidence for the role of CD80 in induction of immune tolerance
Perhaps the most immediate use for manipulation of CD80 comes
from studies in immunosuppression. Blocking with CTLA4 Ig
especially, is able to depress mixed lymphocyte reactions
(MLR)105 and anti-CD80 (B7-24) has been able to depress a
primary MLR to a greater degree than cyclosporin, the
combination showing almost complete inhibition115.
Thus the first role of clinical importance may be to modify acute
graft versus host disease or perhaps to prevent it altogether113.
7.6 CD80 in low grade B cell Lymphoma
In order to assess the role of CD80 augmentation in the immune
response to low grade lymphoma, it was first necessary to look at
expression in some samples since up till then the data were
somewhat sparse.
7.6.1 Anti-CD80 Ig studies
2 anti-CD80 Igs were used in the studies described:
a) BB1 - commercially from Beckton Dickinson. This was
described by Linsely et al98 and bound to Raji cells. It is an
IgG-iK Ig.
b) B7-24 (provided by Innogenetics) described by de Boer et
al101. It was obtained by fusion with splenocytes from a
mouse immunised with SF9 insect cells expressing CD80. It
is an lgG2aK Ig.
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Titration and Comparisons of las
Both antibodies were titrated against a Raji cell line. The optimal
dilution for BB-1 was found to be 1/160 - 1/320 by FACS analysis -
starting concentration of 100pig/1 OOpl.
The optimal dilution of B7-24 was also found to be 1/160 - 1/320 -
starting concentration 200pg/1 OOpl.
The antibodies required a 2nd layer of FITC rabbit F(ab)2 anti-
mouse Ig (Dako) at a dilution of 1/40.
Comparison of the 2 antibodies in the Raji cell line
Both antibodies produced positive results, however the profiles
were not identical suggesting binding to different epitopes. The
DOHH2 cell line did not stain for either.
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Figure 4: CD80 expression in Raji and DOHH2 cell lines as
measured by two antibodies B7-24 and BB-1 (B7-BD)
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As activation of B cells is required to upregulate CD80. Raji cells
were labelled with Hoechst 33242 and cells were analysed using
a FACStar and separated by DNA content and CD80 expression.
No variation in CD80 expression with cell cycle was found.
In view of the small numbers of low grade lymphomas studied for
CD80 expression a larger series was studied by flow cytometry.
12 low grade lymphomas (9 follicle centre cell, 2 B-small
lymphocytic, 1 splenic marginal zone B cell lymphoma). The
lymphoma suspensions were prepared as described before and
the immunophenotyping was carried out using fresh tissue and
then following thawing to make sure that the freezing and thawing
procedure had not affected expression. Phenotyping used BB-1
(Beckton Dickinson).
7.6.2 Expression of CD80 in cultured cells
B7-24 was used to assess CD80 expression in these cells as the
presence of anti-CD40 (IgG-i) meant that when the 2nd layer of
rabbit anti-mouse was applied it would bind to the anti-CD40
leading to a false positive result. Using B7-24 (lgG2a) allowed a
specific FITC-anti-mouse lgG2a to be used which did not react
with IgG-j immunoglobulins allowing measurement of CD80.
7.6.3 Expression ofAdhesion Molecules
As various adhesion molecules are important in costimulation it
was decided to measure expression of CD11a (LFA-1), CD54
(ICAM-1) and CD58 (LFA3) (all Serotec) on lymphoma cells prior
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to and post culture. In addition, HLA-DR (Beckton Dickinson) was
measured to ensure that all the necessary molecules to all these








7.7.1 Initial phenotyping of samples
(a) Fresh
Immunophenotyping of fresh samples revealed poor
expression of CD80. The median proportion of cells
expressing CD80 compared to control was 9% (standard
deviation (SD) 24, range 2-89%). There was no evidence of
a discrete CD80 positive population of the cells.
(b) Frozen
Phenotyping of the same lymphoma cells following thawing
using the antibody B7-24 revealed a median expression of
8% (SD16) range 1-59%.
cultured using IL4 (46pg/L) and anti-CD40
system previously described with the
undergone T and IgD bearing cell depletion
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7.7.2 Cell Viability
Viability of resuspended cells was assessed using 0.2% trypan
blue exclusion, a median viability of 95% (SD3) was seen in the
12 samples studied.
7.7.3 Confirmation of T and IgD bearing cell depletion and clonality
The use of paramagnetic beads reduced the proportion of T cells
from a mean of 34% (SD20) to 8% (SD7) and IgD bearing cells
from 22% (SD17) to 6% (SD7). The cells showed light chain
restriction using 2-colour staining (details of individual results are
shown in Tables 1 and 2).
7.7.4 Bel-2 and adhesion molecule expression
The cells showed low but significant expression of bcl-2. Median
expression of CD11a, CD54 and CD58 was 34% (SD19), 50%
(SD17) and 84% (SD17) respectively.
7.7.5 Analysis of cells harvested after 10-13 days - CD80 and adhesion
molecule expression
Increased expression of CD80 was shown by a shift in median
channel fluorescence. Overall expression increased 16.1 (SD22)
to 62.7 (SD17) per culture (see Figure 5).
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Figure 5: Expression of CD80 (B7-24) compared to lgG2a control isolated
low grade lymphoma B cells before and 10-13 days after growth
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9 = FCL-L10




FCL - Follicle Centre Lymphoma | p0S| Culture
SLL - Small Lymphocytic Lymphoma || pre Culture
MZL - Marginal Zone B cell Lymphoma
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Details of individual lymphomas are shown in Table 2. During
culture a B cell proliferation occurred without evidence of T cell
overgrowth. The cells continued to show light chain restriction on
FACS analysis but there was a shift in phenotype with an increase
in CD19+ve cells and an upregulation in the adhesion molecules
studied. Expression of CD11a, CD54 and CD58 increased to
58% (SD22), 92% (SD14) and 99% (SD2) respectively.
In 4 lymphomas studied for HLA-DR expression this was high at
the end of the culture period.
Table 1
CHARACTERISTICS OF CULTURED CELLS AT DAY 10-13
Sample Histology CD3 IgD CD19 Light
Chain
CD80 CD11A CD54 CD58
1 -L12 FCL 3 40 53 61k 80 81 N/A 99
2-L2 FCL 9 2 68 95k 93 87 96 99
3-L6 MZL 12 49 82 63k 98 53 98 100
4-L3 SLL 4 3 51 99k 55 30 96 97
5-L8 FCL 6 33 58 69k 83 64 90 98
6-L9 SLL 14 2 47 98k 87 49 66 95
7-L7 FCL 2 41 57 95k 75 31 93 97
8-L4 FCL 17 10 25 76k 58 39 68 94
9-L10 FCL 7 18 50 78k 84 35 57 100
10- L5 FCL 19 65 59 61k 74 89 98 99
11 - L11 FCL 5 18 71 75k 88 61 91 99
12- L13 FCL 9 50 65 N/A 70 89 N/A 99
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Table 2
PRE-CULTURE B CELL CHARACTERISTICS FOLLOWING
IGD AND CD3 BEARING CELL DEPLETION
Sample Histology CD3 IgD CD19 Light
Chain
CD80 CD11A CD54 CD58
1 -L12 FCL 13 13 62 90k 0 36 68 87
2-L2 FCL 7 0 27 97k 2 33 64 62
3-L6 MZL 2 2 38 65k 6 53 37 42
4-L3 SLL 7 1 84 99k 4 32 20 86
5-L8 FCL 5 2 35 92k 15 61 49 72
6-L9 SLL 14 1 71 99k 38 26 49 72
7-L7 FCL 4 6 45 96k 4 22 54 96
8-L4 FCL 6 1 13 95k 10 12 44 43
9-L10 FCL 3 8 70 97k 20 45 51 84
10- L5 FCL 20 3 12 83k 24 23 23 65
11 - L11 FCL 2 16 70 97k 8 79 70 77
12- L13 FCL 16 24 30 74k 59 64 75 N/A
Histology Abbreviations: FCL - Follicle Centre Lymphoma
SLL - Small Lymphocytic. Lymphoma
MZL - Marginal Zone B Cell Lymphoma
7.7.6 Discussion
The stromal cell culture system offers the potential to enhance
expression of certain antigens which may be important to the
costimulation of T lymphocytes.
In the past, a drawback has been the apparent change in
phenotype with a loss of mature cell antigens and the
development of blast like morphology34, this has been seen in all
lymphomas studied here. However, the alteration and inter
lymphoma variation of CD19 and IgD bearing cells does not
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appear to affect CD80 expression or the expression of the
adhesion molecules studied. Thus, IL4 can induce CD80
expression in benign111 and malignant B cells; cross linking of
CD40 alone can also induce expression of it in benign cells.
Having shown that the IL4/anti-CD40 system can induce CD80
expression in cultured low grade lymphoma it was necessary to
show that these cells were: (1) more immunogenic than the
uncultured lymphoma cells and (2) that the patient's own T cells
would respond to them.
The IL3/IL10 system whilst producing different phenotypes from
those found with IL4 had not been shown to induce CD80
expression and cells grown on this system were tested for
immunogenicity. It was decided in the first instance to use a
primary mixed lymphocyte reaction to assess immunogenicity of
cultured lymphoma cells.
The use of a primary mixed Ivmphocvte reaction to evaluate the
immunoaenicitv of cultured low grade B cell lymphoma
The combination of antigen presenting cells with T cells should
lead to T cell proliferation if the right signals - HLA Class I and II,
adhesion and accessory costimuli are present. To assess
whether a T cell response would be mounted to cultured low
grade lymphoma - lymphoma cell suspensions were taken and
incubated with T cells (allogeneic and where available autologous)
and the results compared to the same lymphomas cultured using
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IL3/IL10 or IL4 in the stromal cell system using anti-CD40. On
this occasion no T cell depletion was attempted.
T cell proliferation was assessed by the uptake of 3H-thymidine
with radionuclide decay being proportional to T cell proliferation.
Sampling was carried out at several intervals to see if the
response increased with time. Various controls were introduced
and all experiments were carried out in triplicate.
Materials and Methods - the mixed lymphocyte reaction:-
Preparation of presenting cells (stimulators):- 5 lymphomas (L2,
L4, L11 and L13 - all FCL) were taken. Uncultured lymphoma
cells, lymphoma cells cultured in the IL3/IL10 anti-CD40 stromal
cell system and in the IL4 anti-CD40 stromal cell system and
adherent mononuclear cells prepared from peripheral blood acted
as stimulators for the MLR. To culture the lymphomas a 24 well
culture plate was used and 106 viable cells were plated out per
well, 8 wells were used for each culture system. The cells were
harvested at day 10 and immunophenotyped for CD80 expression
(using B7-24) and for CD11a, CD54 and CD58 and HLA-ABC and
HLA-DR. Cells were taken from uncultured lymphomas (same)
and similarly immunophenotyped. To ensure they did not
proliferate they were treated with mitomycin C (50pg/107 cells/ml)
for 30 minutes at room temperature followed by centrifugation (5
minutes, 600g, 25°C) and washing five times in minimal essential
medium.
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Preparation of responding cells
50ml of whole blood was taken, and diluted to 200ml in PBSA.
The diluted blood was centrifuged on a Ficoll Hypaque gradient
(1,000g, 25 minutes, 25°C) the mononuclear layer was removed
and washed twice in PBSA. The monocytes were then removed
by resuspending the mononuclear cells in RPMI supplemented
with 5% FCS and placed in a 250ml Falcon flask (B.D.) rested
horizontally at 37°C for 11 /2 hours. The flask was then stood
upright for 5 minutes leaving behind the adherent monocytes
stuck to the flask.
Setting up the MLR
The stimulators were placed in 96 well round bottomed plates
(Falcon 8077) 3 X 104 cells were placed in each well in 100pl of
RPMI with 10% FCS. To them were added 105 responding cells
(blood lymphocytes) in 100jil of RPMI with 10% FCS. If no
responding or simulators were required then 10Opil of RPMI and
10% FCS without cells was added. The arrangement is shown in
Figure 6.
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Figure 6: Set up of 96 well plates
1-3 4-6 7-9
A IL3/IL10 Cultured Cells


































The cells were pulsed with 3H-thymidine for the last 6 hours of
culture at 3, 5 and 8 days post incubation. The cells were then
frozen and counted. A different plate was used for each period of
incubation.
(1) Immunophenotyping of lymphoma cells pre and post culture
Expression of the adhesion molecules CD11a, CD54, CD58
and the costimulatory molecule CD80 pre and post culture is
shown in Table 3. HLA-ABC was found in all cells where
measured pre and post culture. HLA-DR was present in a
variable number of pre and post culture. Overall, CD11a,
CD54 and CD58 altered in culture although no pattern was
seen in the different culture groups. There was a tendency
for CD11a expression to diminish in culture whilst CD58
tended to increase. CD80 expression increased in cultured
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cells and this was more marked with IL4. An example of
CD80 expression in L2 in the two cytokine systems is shown
in Figure 7.
Table 3: Results
Lymphoma CD1la CD54 CD58 HLA-ABC HLA-DR CD80
L2 Uncultured 65 41 88 100 83 2
L2 IL3/IL10 38 44 67 99 63 37
L2 IL4 32 31 99 99 78 92
L4 Uncultured 12 44 43 100 32 2
L4 IL3/IL10 N/A N/A N/A 100 74 72
L4 IL4 39 68 94 100 83 92
L11 Uncultured 53 11 26 100 63 4
L11 IL3/IL10 89 67 80 100 81 66
L11 IL4 31 36 61 100 82 71
L12 Uncultured 73 40 87 100 76 1
L12 IL3/IL10 46 50 66 98 57 18
L12 IL4 41 61 75 99 67 24
L13 Uncultured 73 14 26 N/A N/A 12
L13 IL3/IL10 28 8 53 N/A N/A 21
L13 IL4 39 6 71 N/A 70 41
N/A = Not available
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Figure 7: CD80 expression in cultured lymphoma cells grown in
IL3/IL10 or IL4
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(2) Mixed lymphocyte reactions:-
In all cases the responding lymphocytes were reactive,
judged by the response to the adherent cells (positve
control), however the background counts varied somewhat
from one experiment to another.
In all cases the allogenic and autologous responses were
greater when cells were cultured in IL4 than in IL3/IL10, with
culture in IL4 these results were substantially higher than the
response to the uncultured cells. In one case, using IL3/IL10
there was little difference between the cultured group and the
uncultured group as far as allogeneic responses were
concerned (L12).
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Table 4: Results of L1108
L1108 Day 3 Day 5 Day 8
IL3/IL10 + Alio 12,350 ±3,100 40,100 ±4,300 177,500 ±45,700
IL4 + Alio 25,900 ±3,500 69,500 ±4,100 380,500 ±46,700
IL3/IL10 + Auto 1,300 ± 340 2,900 ± 700 1,600 ± 340
IL4 + Auto 4,700 ±130 2,900 ±200 3,200 ± 550
IL3/IL10 Alone 1,500 ±500 2,700 ±1,300 1,300 ±320
IL4 Alone 3,600 ±400 2,200 ±200 1,300 ± 100
Uncultured + Alio 5,400 ±100 15,700 ±2,300 54,800 ±23,600
Alio Alone 1,700 ±200 2,100 ± 1,000 9,200 ±5,000
Uncultured + Auto 1,200 ±100 1,200 ±200 1,000 ± 100
Auto Alone 900 ±200 1,100 ±100 600 ±100
Uncultured Alone 1,000 ±100 1,000 ±50 1,350 ±100
Special +ve Only 1,700 ±100 2,100 ±300 2,600 ±400
Alio Responders +
Special +ve Control 13,600 ±1,000 27,000 ±4,000 107,800 ± 12,000
Auto Responders +
Special +ve Control 1,500 ±100 2,100 ±200 10,700 ±2,600
Conclusion: MLR worked - special +ve. controls and allogeneic or
autologous lymphocytes responded. Allogeneic responses -
superior to autologous. IL4 » IL3/IL10. Autologous with
IL3/IL10 - no greater than when cultured cells. Autologous
with IL4 - weak. Although greater than IL3/IL10.
There was evidence that cultured cells much more
immunogenic than uncultured
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Table 5: Results of L13
L1303 Day 3 Day 5 Day 8
IL3/IL10 +Alio 5,800 ± 700 8,900 ±400 10,900 ±2,200
IL4 + Alio 4,200 ± 600 10,900 ±2,800 10,700 ±2,200
IL3/IL10 + Auto 1,800 ±200 9,800 ±1,700
IL4 + Auto 5,000 ±700 5,200 ±1,000
IL3/IL10 Alone 1,800 ±200 2,400 ± 700 3,100 ±800
IL4 Alone 1,800 ±200 2,000 ± 200 2,300 ±300
Uncultured + Alio 2,600 ± 200 3,600 ±300 3,800 ±800
Uncultured + Auto 1,000 ±100 5,300 ±1,000
Uncultured Alone 1,500 ±600 3,100 ±400 1,700 ± 200
Special +ve Alone 2,300 ± 1,000 1,900 ±200 1,400±100
Alio + Special +ve 4,200 ±100 6,100 ±300 7,600 ±300
Auto + Special +ve 550 ±100 4,700 ± 800
Auto Alone 4,070 ± 100 2,300 ± 400
Alio Alone 3,000 ± 200 2,300 ±100 2,700 ± 200
Conclusion:- MLR worked, the allogeneic responses were superior to the
autologous ones. In this case although responses occurred
earlier in the cultured cells they were eventually matched by
those in the uncultured group. IL4 cultured cells elicited
stronger responses than IL3/IL10.
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Table 6: Results of L2
L218 Day 3 Day 5 Day 8
IL3/IL10 + Alio 6,000 ± 1,600 8,200 ± 1,600 8,000 ± 1,400
IL4 + Alio 8,000 ±900 15,200 ±2,300 14,500 ±2,800
IL3/IL10 + Auto 7,000 ± 800 4,800 ±1,000 6,800 ±1,700
IL4 + Auto 9,200 ±500 13,100 ± 1,900 14,700 ±2,800
IL3/IL10 Alone 2,500 ± 200 2,100 ±700 4,800 ± 900
IL4 Alone 2,500 ±300 1,900 ± 700 4,200 ± 300
Uncultured + Alio 3,200 ± 300 6,300 ± 700 6,800 ±1,100
Uncultured + Auto 3,600±100 4,100 ±300 5,200 ± 100
Uncultured Alone 1,400 ±200 1,400 ±300 1,700 ± 300
Special +ve Only 1,400 ±200 1,400 ±200 1,900 ±200
Alio + Special +ve
Control 2,900 ±300 5,000 ±1,100 8,700 ±800
Auto + Special +ve
Control 3,500 ±100 6,700 ± 300 11,400 ±1,000
Auto Alone 2,800 ±20 2,800 ±50 3,300 ±100
Alio Alone 2,200 ± 500 2,100 ±100 3,100 ±10
Conclusion:- MLR worked. Cultured cells lead to stronger respones than
uncultured. Allogeneic and autologous responses were
equivalent. IL4 cultured cells lead to stronger responses
than IL3/IL10.
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Table 7: Results of L4
L404 Day 3 Day 5 Day 8
IL3/IL10 Alio 15,600 ±1,300 32,700 ±1,400 129,900 ± 17,600
IL4 Alio 16,300 ±5,800 58,500 ±1,500 243,100 ±19,800
IL3/IL10 Alone 2,300 ± 500 1,200 ±100 1,600 ±100
IL4 Alone 1,500 ±100 1,400 ± 200 1,200 ±200
Uncultured + Alio 5,200 ±900 13,100 ±1,700 40,500 ±8,000
Uncultured Alone 1,000 ±100 1,000 ±50 900 ±100
Alio + Special +ve
Control 11,100±1,100 22,500 ±3,400 90,200 ±8,200
Alio Alone 2,600 ±500 5,800 ± 1,400 14,400 ±8,000
Special +ve Control
Alone 1,700 ±100 2,100 ±300 2,600 ± 400
Conclusion:- MLR worked. Cultured cells lead to stronger responses
than uncultured cells. No autologous lymphocytes were
available.
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Table 8: Results of L12
L1205 Day 3 Day 5 Day 8
IL3/IL10 +Alio 300 ±50 150 ± 50 50 ±20
IL4 +Alio 650 ±50 250 ±100 450 ± 200
IL3/IL10 + Auto 650 ±100 500 ±300 950 ±400
IL4 + Auto 1,700 ±100 1,100 ±400 4,000 ±1,500
IL3/IL10 Alone 60 ±10 10±0 50 ±30
IL4 Alone 150 ±50 50 ±10 20 ±0
Uncultured + Alio 150 ±50 40 ±30 100 ±50
Uncultured + Auto 450 ±100 550 ±150 5,500 ±1,700
Uncultured Alone 30 ±0 10 ± 0 20 ±0
Special +ve Only 150 ±0 100 ±30 100 ±50
Alio + Special +ve
Control 600 ±100 1,300 ±200 13,900 ±1,900
Auto + Special +ve
Control 1,400 ±100 4,800 ±500 17,600 ±2,900
Auto Alone 150 ±100 350 ±200 550 ±500
Alio Alone 50 ±0 20 ±0 20 ±0
Conclusion:- Counts generally low, but special positive controls confirmed
that both allogeneic and autologous cells were capable of
responses. Autologous responses were greater than
allogeneic ones, although some responses with uncultured
cells were equivalent to those using IL3/IL10 cultured cells.
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Discussion
The experiments described suggested that there had been a
change in the immunogenicity of the cultured cells as judged by a
primary mixed lymphocyte reaction. The 5 follicle centre
lymphomas all of which had low expression of CD80 prior to
culture appeared unable to elicit a significant allogeneic mixed
lymphocyte reaction particularly early on (day 3) although there
had been a rise by day 8. The autologous responses in the 4
uncultured lymphomas studied were weaker than their allogeneic
counterparts in 3 cases (L218, L1303 and L1108) but stronger in
L1205 - a case where the allogeneic response was particularly
weak despite the fact the allogeneic response in this case to the
special positive control was strong - suggesting that no
impairment of the response existed with the allogeneic
lymphocytes. As these lymphoma cells possessed MHC Classes
I and II and CD54; CD58 and CD11a and these can induce an
allogeneic response113 perhaps this is not surprising.
In culture, where these lymphoma cells had been induced to
express CD80 in both the IL4/anti-CD40 system and the IL3/IL10
anti-CD40 system with continuing although varying expression of
the other adhesion molecules the MLR would be expected to be
stronger. In all cases CD80 expression was stronger in the IL4
group than the IL3/IL10 group, although CD54 appeared to be
more expressed in the latter. The allogeneic responses to
cultured cells in both groups were much stronger than in the
uncultured, with the result in IL4 generally being stronger. As far
as the autologous response was concerned a stronger response
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was seen for the IL4 group in cases L1108, L218, L1205. In
L1303 the responses were very similar.
In two cases the autologous responses were weaker than the
corresponding allogeneic ones (L1108, L1303), equivalent in one
(L218) and stronger in one (L1205). In one case (L218) the
IL3/IL10 cultured cells autologous response was no greater than
that achieved with uncultured lymphoma cells. As CD80
expression was higher with IL4 the fact that these cells produced
stronger MLRs would be in fitting with the expected result. There
did not appear to be a relationship between the number of cells
expressing CD80 and the strength of response suggesting that
perhaps a small degree of upregulation would be sufficient - if
CD80 is the reason for the enhanced MLR.
CD80 expression is directly induced by IL4 and anti-CD40, the
lower expression in the IL3/IL10 cells would be expected as one
cause of upregulation (IL4) is absent. In fact IL10 has been
shown to reduce CD80 in monocytes54 and IL3 is not known to be
an inducer of CD80 expression presumably the only exogenous
stimulus in these cells was anti-CD40.
The ability of cells with relatively low CD80 expression (although
increased compared to the uncultured cells) to elicit a strong MLR
may also be taken as suggesting the role of other adhesion
accessory molecules to be important. In particular CD86 (B7.2)
and B7.3 were not measured and it may be that some
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compensation from these antigens in the low CD80 expressing
cells was possible.
The discovery that CD80 expressing melanoma cells were able to
act as tumour vaccines in a murine model was the major prompt
for this work. The situation is complicated by the fact that the
lymphoma cell is acting as antigen presenter - as a malignant cell
and as a normal B cell - in its response to cytokine driven CD80
induction.
The fact that autologous MLRs occurred which were stronger with
the cultured cells particularly the IL4 cultured cells is encouraging,
as this suggests it may be feasible to culture a patients lymphoma
in vitro - using IL4/anti-CD40 (as this not only produces stronger
MLRs than IL3/IL10 group but also leads to a greater growth rate
with the generation of more cells), take these cells and inject them
into the patient and they then could activate the patients own T
cells to generate an immune response.
Whilst the experiments described show a greater MLR occurs with
cultured cells whether the reaction generates cytotoxic
lymphocytes is currently unknown and it has not been proven that
the presence of CD80 is what is responsible for the enhancement
of the MLR. Specific blocking experiments using anti-CD80 or
CTLA4 Ig would be required to assess the contribution of
upregulating the CD80 system to enhancing the MLR.
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In summary, in vitro culture of lymphoma cells using a stromal cell
system is able to enhance the immunogenicity of these cells
particularly if grown IL4 and upregulate CD80 expression - this is
seen with both allogeneic and autologous T lymphocytes.
Whether CD80 expression is the cause of the enhanced MLRs
remains to be determined.
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CHAPTER 8
CALCIUM CHANNEL BLOCKADE - DIHYDROPYRIDINE
AND RYANODINE RECEPTOR SYSTEMS
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8. CALCIUM CHANNEL BLOCKADE - DIHYDROPYRIDINE AND
RYANODINE RECEPTOR SYSTEMS
8.1 Introduction
The observation that bcl-2 expression might lead to apoptotic
supression and that calcium flux modification might attenuate or
enhance this lead to attempts to modify calcium flow to alter
cytotoxic drug sensitivity in bcl-2 producing cells. It became
apparent that the ryanodine receptor antagonists dantrolene and
azumolene were able to induce cell death directly and studies on
the timing and dosing of these agents are described as are
detailed comparisons with conventional cytotoxic drugs. Cell line
work is presented initially followed by results obtained in primary
culture using the IL3/IL10 stromal cell system.
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Bcl-2- the regulation of appptosis and alterations in calcium flux
The realisation that uncontrolled cell division was not the only
cause of tumour development, but that failure of cell death could
lead to the accumulation of tumour cells and indeed that this might
be the predominant mechansim of growth in slow growing
tumours has opened the door to new strategies designed at
augumenting this process. The process of programmed cell death
or apoptosis - originally described by Wyllie et al in 1972 requires
nuclear shrinkage116 with DNA degradation followed by
membrane permeability changes.
Bcl-2 - a major anti-apoptotic protein - now considered a member
of a large family of such compounds was first found to be
upregulated in follicle centre lymphoma - by virtue of the t(14;18)
which placed it under the control of the IgH (immunoglobulin
heavy chain) enhancers62. This translocation - originally thought
to be pathognomonic of such lymphomas is now known to occur
in benign lymphoid tissue B cells62. It is now becoming clear that
over expression of bcl-2 per se is not sufficient for an anti-
apoptotic effect. Heterodimerisation with bax is usual - and
inhibition of bax homodimerisation may be the main mode of its
action. In normal lymphocyte development, bcl-2 expression
varies - being high in B cell precursors63-117 falling at the pre-B
cell level before rising again with further maturation. Upregulation
at normal stages of low expression may allow malignant cells a
significant growth advantage. Bcl-2 expressed by B cells is a long
lived protein with a t1/2 of about 10hrs117 - low grade lymphomas
lacking t(14;18) also produce it e.g. B-CLL118 - and it may be
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upregulated by cytokines e.g. IL450. Apoptosis induced by DNA
damage can also be inhibited by bc/-2119'120, whilst other
members of the family e.g. bc/-^121 - a bcl-2 homologue, may act
as the dominant apoptotic suppression protein, as may viral
proteins e.g. EBV-BHRF-1122 which may take on the role of bcl-2
when this is not expressed. Bcl-2 action is downstream of DNA
repair, or nucleotide pools62. It is a 25-26 kd protein present in
the ER, nuclear envelope and outer mitochondrial membrane.
Calcium flux changes between the various intracellular
compartments appear to occur during apoptosis and may be
modulated by bcl-2. In a hematopoietic cell line which is IL3
dependent123, transfection with bcl-2 can reduce apoptosis.
Without bcl-2, Ca2+ enters the cytosol but with it no change
occurs. There appears to be two major stores of calcium: (1)
Non-Mitochrondrial - especially123 - endoplasmic reticulum (ER)
(high affinity, low capacity) and (2) Mitochrondrial.
Thapsigargin which inhibits Ca2+ ATPases leads to discharge of
calcium from non-mitochrondrial stores leading to an initial
cytosolic rise followed by a gradual fall in calcium. In an IL3
dependent cell line, on IL3 withdrawal thapsigargin mobilised less
calcium in bcl-2 lacking cells. Mitochondrial calcium levels rose in
the absence of bcl-2. Calcium ionophores e.g. ionomycin lead to
a cytosolic rise in calcium and suppression of apoptosis in bcl-2
lacking cells123. It seems that in the absence of bcl-2 there is a
shift of Ca2+ from the ER and cytosol to the mitochrondria.
Alteration of Ca2+ flux may be able to attenuate or enhance
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apoptosis. The effects of bcl-2 may not be confined to
calcium2124. It appears to affect lipid peroxidation and oxygen
free radical synthesis and this may represent an important
mechanism of action. Bcl-2 does not act in isolation and
interactions with various oncogenes has been seen125.
C-myc expression leads to mitosis and apoptosis. Apoptosis is
mediated by a secondary rise in p53, co-ope rativity between bcl-2
and c-myc leads to suppression of c-myc induced apoptosis125'126
but not in its mitogenic role. Cytokines in addition to bcl-2 are
able to suppress c-myc induced apoptosis72. Insulin like growth
factor (IGF-1) and platelet derived growth factor (PDGF) have also
been shown to do this as well72.
Bcl-2 and Chemotherapy
In a leukaemia cell line120 bcl-2 protects against the cytotoxicity of
dexamethasone, methotrexate, cisplatin, cytarabine and
etoposide. Interestingly, its protective effect against vincristine is
incomplete. Other studies suggest that the relative protection
afforded by bcl-2varies from one drug to another127 - with some
e.g. 4 hydroperoxycyclophosphamide or etoposide it is mild, with
others e.g. cladribine, methotrexate - it may amount to a one
logarithim difference. In acute myeloid leukaemia128 a high level
of bcl-2 predicts a poor response to chemotherapy.
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8.3 Calcium channel blocking drugs - the dihvdropvridine and
hvdantoin derivatives
The use of calcium channel blocking drugs as therapeutic tools is
well established in clinical practice. Most of these drugs block the
inward flux of calcium by attaching themselves to extracellular
voltage dependent receptors which are present in smooth muscle
lymphocytes and myocardial cells129. Their main role is in the
treatment of cardiovascular disorders - angina, hypertension and
the prevention of secondary vasospasm following subarachnoid
haemorrhage. Nimodipine (Figure 1), a dihydropyridine derivative
was used to block extracellular to cytosolic calcium flux.
Dantrolene sodium (Figure 2), a hydantoin derivative130 or its
water soluble analogue azumolene131'132 (Figure 3) have been
used in the treatment of malignant hyperthermia. They bind to the
ryanodine receptor in skeletal muscle133 and prevent the release
of calcium from the sarcoplasmic reticulum. Dantrolene binding
sites have been found in neural tissue133*135 and also in murine
lymphocytes136.
Azumolene is structurally related to dantrolene but has a bromo
group substituted for a nitro group in the C1 benzene ring and



















Azumolene is approximately 30 times more soluble than
dantrolene131 and in vivo studies in malignant hyperthermia
susceptible pigs suggest it to be equipotent131 as do studies in rat
soleus muscle137. However, in vivo - dantrolene appears three
times more potent than azumolene138 as far as skeletal muscle
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relaxation is concerned. It has also been noted to affect Ca2+
release induced by doxorubicin from skeletal and cardiac
muscle139. This effect was most prominent in skeletal muscle and
azumolene appeared to bind the sarcoplasmic reticulum at sites
distinct from calcium binding sites and inhibit calcium release by
competing with doxorubicin at the drug receptor. It seemed as
though the binding were not directly to ryanodine binding sites, but
that competition for the doxorubicin binding site occurred which
reduced the ability of the drug to cause Ca2+ release from the
sarcoplasmic reticulum.
The natural agonist at the ryanodine receptor appears to be cyclic
ADP-ribose (cADPR)140 which with members of the inositol
polyphosphate family141'142 control the influx of calcium from the
endoplasmic reticulum to the cytosol. The potent
immunosuppressant tacrolimus (FK506) binds to a protein which
alters ryanodine receptor function143 and blocks calcium release
in an asymmetrical fashion144. Interference with cADPR synthesis
from NAD by cladribine (2CdA) a profoundly lymphotoxic drug
leads to cell death by apoptosis12. As the partitioning of calcium
between the endoplasmic reticulum and the cytosol seems
important in preventing cell death and this is affected by bcl-2 -
modulation may either be expected to induce death directly or at
least enhance the ability of cytotoxics to do so. This provided the
rationale for investigation of nimodipine, dantrolene and
azumolene firstly in 3 lymphoma cell lines with varying
expressions of bcl-2 (Vallois - very high; DOHH2 - high; Karpas -
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Nil) and then in primary cultured low grade B cell lymphoma using
the IL3/IL10 anti-CD40 stromal cell system.
In addition, as it had been suggested that a neuroblastoma cell
line grew unaffected by dantrolene145 and that this blocked the
growth suppressing effects of oestrogens and anti-oestrogens by
interfering with second messenger calcium systems a titration
study to see if neuroblastoma cells responded differently to
lymphoma in the presence of dantrolene was carried out.
Schematic diagram of calcium signalling (Figure 4)
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Figure 4: Calcium Signalling - the cADP ribose and Inositol
Polyphosphate Receptor Systems
Nitric oxide PDGF, EGF etc
Complete blockade of either the ryanodine or inositol
polyphosphate systems can lead to compensation by the
unaffected one146.
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8.5 Materials and Methods
8.5.1 Cell Lines
a) The DOHH2 cell line (t 8;14;18) kindly provided by P. Kluin,
University of Leiden147 - a transformed follicle centre
lymphoma expressing bcl-2.
b) The Vallois cell line147 - a lymphoma cell expresing large
amounts of bcl-2 - with a complex translocation.
c) The Karpas 1106 cell line148 - a lymphoma cell line with a
complex translocation involving 18q21.3 but lacking bcl-2
rearrangement and expression.
d) The SKNSH cell line - a neuroblastoma cell line expressing
bcl-2.
All cell lines were grown in RPMI base medium (described in
Chapter 2). The DOHH2, Karpas and Vallois cell lines were
grown with a starting concentration of 106/ml in Falcon 25ml flasks
-10ml per flask. The neuroblastoma cell line was grown at an
initial concentration of 105/ml. These grew adherently to the flask
and required EDTA 2mmol/L to free them.
Cell counts were manually carried out using a hemocytometer




RMM 418 - supplied by Bayer A.G. Yellow crystalline
powder laevorotatory form responsible for calcium channel
blockade. Light sensitive - in presence of UV light f/2 =
16hrs; in daylight f/2 = 56hrs.
In vivo - Action is seen at 2.5 x 10_7M (0.25|imol/L).
- Insoluble in H2O - soluble in ethanol.
Range studied 0.01 - 1pmol/L
Solution preparation:- 1 mmol/L = 418mg/L
per 10ml = 4.18mg
per 20ml = 8.24mg
Therefore for 10ml solution: 10pil/10ml = 1 pmol/L
1 jj.l/10ml = 0.1pmol/L
0.1 pil/10ml = 0.01(imol/L
b) Dantrolene Sodium
RMM 399 (hydrated) orange powder; slightly soluble in H2O.
Therapeutic range 5-10|imol/L. Solubility in physiological pH
aqueous solution = 37pmol/L - maximum. For higher
solubility either use organic solvent - 1, 2, 3 propanetriol
(glycerol) - requires sonication or adjust pH with NaOH.
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Preparation using propanetriol 25mg/10ml
1 ml/1 Oml = 600|imol/L
0.1 ml/10ml = 60pmol/L
10(il/10ml = 6|imol/L
1 (j.l/1 Oml = 0.6|imol/L
Dantrolene in Mannitol/NaOH/H20 - used for primary culture with:
50mg dantrolene +
1 OOjj.1 of 1 molar NaOH +
75ml H2O (distilled) +
5g/Mannitol
Therefore: 50mg/75ml = 0.67g/L
Mixture was sonicated for 2 minutes and stored in the dark for
48hrs maximum.
RMM = 399 = stock solution = 1.675 x 10"3m/L
1.675 millmol/L
1.675(imol/L
For 40jimol/L = 0.4pmol/10ml.
0.4 L = 2.38 x 10"4L - 240(il solution
1675





Dantrolene autofluorescence in the FL-2 band
In glial cells autofluorescence suggested uptake134. This was







Figure 5: Dantrolene uptake into DOHH2 cells assessed by
autofluorescence.











RMM hydrated 453. Isotonic solution 10mg/ml; water soluble
white powder. At 9.06mg/ml = 20mmol/L (stock solution).









This was carried out using flow cytometry. Cells were suspended
in medium at a concentration of no more than 106/ml. To 1ml of
suspension were added 10Opil of propidium iodide (PI) (50jig/ml)
and 10Ojj.1 of Hoechst 33342 (10pg/ml). The cells were analysed
after incubation for 2 minutes at room temperature. A dual laser
FACStar was used. The primary laser was set at 488nm to excite
PI and the secondary laser at the UV wavelength (351.1 - 363.8)
to excite the Hoechst. Both signals were logarithmically amplified
with PI fluorescence being detected above 600nm (FL-2 band)
and Hoechst fluorescence between 390-460nm (FL-1 band).
Results were displayed as a quadrantic plot with Hoechst uptake
along the X axis and PI uptake along the Y (see Figure 6).
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Figure 6: Quadrantic plot showing uptake of Hoechst












Those cells which took up neither dye were deemed to be viable,
those which took up both were deemed to be dead149>15°.
As Hoechst influx is time dependent, all analyses were carried out
in the first 5 minutes as eventually all live cells would take up
Hoechst. In primary culture, a cruder method of assessment was
used by looking at the left shoulder of a PI histogram. This
represented the degraded DNA. The higher the percentage in this
region compared to the total the greater the number of apoptotic
cells. This was compared to untreated controls.
8.5.4 Viable Cell Count
In all experiments described, the viable cell count is the total count




To ascertain whether azumolene had any effect on cell cycle the
DOHH2 cells were stored with BrdU for varying periods of time -
24, 48 and 72hrs prior to fixing and analysis using FACS.
Cells were treated with 10(imol/L BrdU incubated in RPMI base
for the allotted time period and then fixed in 70% ethanol at 4°C.
A pellet was prepared and the cells washed twice in PBS. The
cells were resuspended in 2M hydrochloric acid and left for 30
minutes at room temperature.
The mixture was then centrifuged and washed in PBS X2 and
PBS-T (PBS + 0.1% bovine serum albumin + 0.2% Tween 20 pH
7.4) and stained with 50(il anti-BrdU antibody (Sera-Lab) for 20
minutes at room temperature followed by washing 2X in PBS-T.
2nd layer staining using FITC rabbit anti-mouse F(ab)2 fragments
(Dako) 50pl at 1/10 dilution for 20 minutes at room temperature.
The cells were washed in PBS and treated with 100pl
ribonuclease (1mg/ml; Sigma) for 15 minutes at room
temperature. 300pl PBS and 10Opil propidium iodide. 50|ig/ml
were added and left for 10 minutes. Analysis was carried out by
flow cytometry - with gating out of debris using forward and side
scatter.
177
8.6 Results and Statistical Analysis
All results quoted are the mean of experiments which were carried
out in a minimum of two times.
Statistical analyses were carried out by balanced multiple analysis
of variance (Minitab, Ver 10, Ohio, USA). The residuals from this
were tested to confirm normality of distribution. This was found to
be the case (p>0.1) except in the case of nimodipine alone (Figure
9) (p = 0.01). However, as there was clearly no effect with
nimodipine no non parametric analysis was performed.
8.6.1 Prolonged culture with continuous dantrolene and/or nimodipine in
the DOHH2 (Figures 7, 8, 9)
The total viable count was analysed at 72 and 156hrs. Cell death
was progressive, with a fall in cell numbers apparent at 72hrs.
Dantrolene was studied at 3 concentrations - 60, 30 and 15jj.mol/L
and nimodipine at 1, 0.5 and 0.25pmol/L. Balanced analysis of
variance for time and treatment revealed a significant effect
(p<0.01). No advantage over single agent dantrolene was seen (p
= 0.859). Only the higher concentration (D - 60|imol/L) actually
reduced cell numbers compared to the starting amounts, whilst in
the lower concentration a growth retarding effect was seen. No
evidence of activity for nimodipine alone was observed (p = 0.645)
(Figure 9). Eventually the maximum effects of dantrolene
matched those of the combination, but it took longer. Flow
cytometry showed the mode of death to be necrotic, with minimal
induction of apoptosis.
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4.6.2 Single agent dantrolene in the Karpas and Vallois, DOHH2 and
SKNSH cell lines 168hrs incubation (Figures 10-13)
Following the demonstration of a significant cytotoxic effect of
dantrolene in the DOHH2 cell line the 2 cell lines with differing
levels of bcl-2 expression as assessed by flow cytometry were
used to assess dantrolene activity. The cells were exposed to
varying concentrations of dantrolene for 168hrs and then the
viable cell count calculated. The results confirmed the Vallois line
with the highest level of bcl-2 production to be the most sensitive,
the Karpas line which produced no bcl-2 was less sensitive
(Karpas vs Vallois p = 0.054), however it was also growing more
slowly and the DOHH2 which grew the quickest was actually least
sensitive (Karpas vs DOHH2 p = 0.5, DOHH2 vs Vallois p = 0.09).
This suggests that if bcl-2 is responsible for the difference, no
correlation between the level of bcl-2 production and the degree of
resistance to dantrolene can be inferred. It is reassuring that the
Karpas line which was growing significantly more slowly was more
sensitive than the DOHH2 suggesting that cell growth rate was not
the determining factor.
The SKNSH cell line
Cells were incubated for 168hrs with dantrolene at: 20, 40 and
60pmol/L prior to assessing the viable cell line. The line
expressed bcl-2 strongly (see Figure 14 - FACS analysis). The
line seemed much less sensitive to dantrolene than the lymphoma
lines.
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Figure 14: FACS histograms showing bcl-2 expression in the Vallois,
DOHH2, Karpas and SKNSH cell lines
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8.6.3 Azumolene Titration
Azumolene was titrated for effect in the DOHH2, Karpas and
Vallois cell lines. As previous studies had suggested it to be
equivalent as far as muscle relaxation was concerned a range of
5-20|imol/L was selected. In the 3 cell lines a dose response was
seen with azumolene 10pmol/L ~ dantrolene60pmol/L. The
results in the 3 cell lines are shown compared to dantrolene
(Figure 15).
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Figure15:72h sAzumolene-cellou tat168hrs DOHH2
Vallois
CellLines
Scheduling ofAzumolene (Figures 16 and 17)
Since azumolene had been found to be as efficacious, although
significantly more potent than dantrolene, further studies were
carred out to see if its effect on cell lines were schedule
dependent, and if the effect of a short incubation period were as
effective as a longer one. The following were investigated.
(1) 168hrs continuous azumolene - cell count at 168hrs (Figure
14).
(2) 72hrs azumolene - cell count at 168hrs.
(3) 24hr azumolene - cell count at 168hrs.
(4) 24hr azumolene divided in four 6 hourly exposures at 24hr
intervals - with cell count at 168hrs.
The experiments were carried out in the DOHH2 and Vallois cell
lines. For the 24 and 72hr experiments samples were washed in
RPMI base medium and washed twice before resuspension in
RPMI base for culture. This was carried out at the end of each 6














24hrfractionated Azumolene4X6hr over96hfollowed by72hrfree
Vallois
Figure 18: Diagram of 4 X 6 hourly fractionated Azumolene scheme
Final Cell Count
A Nil A Nil A Nil A Nil
► ► ► ► ► ► ► ► > ▼
6h 18h 6h 18h 6h 18h 6h 18h 72hr
A = Azumolene
Continuous exposure to Azumolene over 168hrs lead to the best
results. 72hrs showed intermediate results (72hrs vs 168hrs p =
0.08) whilst 24hrs continuous exposure followed by 144hrs
recovery in Azumolene free medium appeared the weakest.
Fractionating the dose in to four 6 hourly exposures appeared to
enhance the effect (24hrs vs 4 x 6hrs p<0.001) but it still remained
inferior to the 72 or 168hrs exposure groups. The fact that 24hr
exposure given as 4 X 6 hourly exposures in 96hrs was more
effective than 24hrs in one go suggests that intracellular levels
may be maintained. In experiments carried out on the primary
lymphoma cell line specimens continuous exposure was used for
fear of disrupting the growing cells from the monolayer with
repeated washes.
8.6.5 BrdU analysis and apoptosis assessment - using Flow Cytometry
- (see Figures 19 and 20)
There was no evidence that cell cycling was arrested by
azumolene at any time or at any concentration studied suggesting
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that any cytotoxic effect of azumolene is non cell cycle specific.
This was the case in the DOHH2 and Vallois cell lines. Repeated
sampling at 24 hourly intervals for evidence of apoptosis showed
evidence of this particularly at the higher concentrations
(Azumolene 10 and 20pmol/L). It was seen in the DOHH2 cell line
but not in the Vallois line and as this expressed bcl-2 to a greater
degree than the DOHH2 line - this is further evidence that
azumolene did not exert its cytotoxic effect via bcl-2 interruption.
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8.6.6 Ryanodine receptor antagonists in primary lymphoma culture (see
Figures 21a + b and 22)
The experiments were carried out using the stromal ceil system
previously described. 24 wells were set up. The difficulty in
changing the medium without disrupting the lymphoma cells and
fibroblasts meant only continuous exposure to dantrolene or
azumolene could be investigated. The lymphoma cells were
cultured on the monolayer for 3-5 days to ensure they were
established prior to the addition of the drugs which were then
applied for 120hrs prior to analysis. 4 wells were treated per drug
and cells harvested at the end of the experiment fro the 4 wells,
centrifuged and resuspended in exactly 1ml PBSA. Counting was
carried out using a haemocytometer, viability was assessed with
trypan blue as before. 2 concentrations of dantrolene were used -
60|imol/L and 30(imol/L in the 1st experiment. In the comparison
with azumolene 60jimol/L of dantrolene was compared to 6(imol/L
of azumolene. 60(imol/L and 30|imol/L of dantrolene appeared
equivalent, and 60pmol/L dantrolene appeared similar to 6jimol/L
azumolene.
There did not appear to be any relationship between the
sensitivity of a particular culture to the ryanodine receptor
antagonists and the level of bcl-2 expression.
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Figure 21a
The effect of dantrolene at 2 concentrations in 5 low grade lymphoma
cultures.
Histology FCL SLL FCL FCL FCL
L211 L304 L503 L1003 L1203
Growth Fraction (%) 7 3 6 6 10
Day 1
Day 10 7 2 4 6 11
Bcl-2 Expression %
versus negative control 97 0 9 47 92
Day 1
Day 10 36 93 35 80 6
The effect of dantrolene versus that of azumolene in 3 lymphoma
cultures.
Histology FCL FCL FCL
L214 L802 L903
Growth Fraction %
Day 1 7 10 7
Day 10 7 N/A 6
Bcl-2 Expression %
versus negative control
Day 1 97 4 92
Day 10 36 N/A 89
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In primary culture 6|imol/L azumolene was used. As cell line work
suggested 10|imol/L to be equivalent to 60(imol/L dantrolene, the
inferior results obtained here with 6|imol/L azumolene are not
surprising. There appeared to be no correlation between growth
rate or bcl-2 expression and senstivity to these agents.
Compared to cell lines, the primary cultures appeared relatively
resistant to both these drugs.
Assessment ofApoptosis
In L214, L802, L903 there was no evidence from PI histograms
that death was via apoptosis in the treated cells.
Discussion
The experiments described, suggest that dantrolene and
azumolene have cytotoxic activity in various lymphoid cell lines
and more importantly in primary lymphoma culture. Dantrolene
appears less potent, although maximal efficacy of the two appears
the same. The initial assumption that deregulation of bcl-2 action
is responsible for this effect is not strongly supported by the
evidence presented. Although the most strongly expressing bcl-2
cell line was most sensitive to the ryanodine receptor antagonists,
there was little difference between the DOHH2 and the Karpas cell
lines which produced some and no bcl-2 respectively, and no
relationship could be seen in the primary lymphoma cultures.
Fractionation of dose of azumolene appeared more effective than
a single exposure in the DOHH2 cell line suggesting that there
may be some schedule dependency. The concentrations of
dantrolene required for its effects seen here were much higher
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than studies into its actions on muscle relaxant with effects being
maximal in the 10|imol/L range119. In vitro work has used
concentrations of up to 300(imol/L133. Suppresion of intracellular
calcium mobilisation needed to stimulate gluconeogenesis in rat
hepatocytes has been achieved using 60|imol/L of dantrolene151.
Very high concentrations have been given to humans with doses
likely to produce plasma levels of 40-50pmol/L - without ill
effect152. High concentrations administered to beagle dogs using
lyophilised dantrolene/mannitol and NaOH confirmed a 54%
inhibition of skeletal muscle contraction in doses producing levels
of 55-60pmol/L with no effect on heart or blood pressure153.
Azumolene, on the other hand produced significant effect at or
slightly above those levels established as being equivalent to
dantrolene 10|imol/L154 as far as skeletal muscle relaxation is
concerned and this suggested that it have a higher therapeutic
index.
Nimodipine appeared a comparatively disappointing agent. It has
little activity alone and combination with dantrolene was no better
than dantrolene alone. This may be because most cytosolic
calcium changes depend on repartitioning between endoplasmic
reticulum and cytosol, rather than receiving calcium from the
extracellular space134. A similar calcium channel blocker -
verapamil has been reported to cause inhibition of B cell
proliferation in vitro and induce clinical reponses in B cell CLL
which might be due to tumour necrosis factor (TNF), release
inhibition155. In addition, there is some evidence that both
dantrolene and azumolene may antagonise dihydropyridine
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receptors as well as ryanodine ones156 thus reducing the
additional role of nimodipine.
The timing of cell death suggests a novel action for these drugs
as compared to conventional cytotoxics with minimal effects being
seen in the first 48 hours. Whilst a cytotoxic action may be
postulated for concentrations over 40mmol/L dantrolene
(>10|imol/L azumolene) a cytostatic action occurs at lower doses
in cell line studies. In primary culture there seems little difference
between concentrations of 30 or 60pmol/L.
A cytostatic action may be useful in slow growing tumours. The
most appropriate schedule for investigation appears to be
azumolene administered daily by bolus injection or short infusion
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9. DRUG SENSITIVITY TESTING - IN CELL LINES AND
PRIMARY LYMPHOMA CULTURE
9.1 Introduction
In vitro drug sensitivity testing is an area of research which still
has to overcome significant problems if it is to make a contribution
to the management of individual patients as opposed to simply
identifying new agents which are worthy of further study. Most in-
vitro work has been carried out using cell lines, however, these fail
to retain certain features of the parent tumour. They may have
lost their dependency on local growth factors and may simply
represent the most aggressive and rapidly dividing element of a
tumour. They are nevertheless, easy to work with and large
numbers of cells may be cultured allowing experiments to be
repeated numerous times.
For in-vitro work to be more representative it is necessary to grow
the parent tumour and hope it retains many of its in vivo
characteristics.
This chapter examines the use of various cytotoxic drugs in the
lymphoma cell line (DOHH2) and compares the results with those
obtained using the IL3/IL10 stromal cell system for primary
lymphoma culture. The dihydropyridine - nimodipine and the
ryanodine receptor antagonist dantrolene are combined with
cytotoxic drugs to study the effects in this cell line to look for
synergy.
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Many normal and cancer cells are able to remove toxic
compounds by an energy consuming process involving the
production of P-glycoprotein. Some cells have this system
activated, in others it needs to be induced. The synthesis of P-
glycoprotein in cancer cells is a mechanism for acquired drug
resistance. It has been observed that verapamil and nifedipine
are able to reverse drug resistance by blocking the influx of
calcium and antagonising the P-glycoprotein system. Although it
has not been reported that nimodipine or dantrolene are able to
affect this system, it may be that they do and that this is
responsible for at least part of their activity in combination with
cytotoxic drugs. It however does not explain the activity they have
alone in the absence of cytotoxic drugs. The DOHH2 cell line and
some primary lymphoma cultures are surveyed for their ability to
produce P-glycoprotein. Finally, the results of the cytotoxic drugs
are compared with those of the ryanodine receptor antagonists
seen in the previous chapter.
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9.2 Materials and Methods
9.2.1 Dose finding of cytotoxic drugs in the DOHH2 cell line
Table 1




1. Fludarabine Schering Dry powder preservative





- Dry powder - dissolve in
ethanol - 3mg/ml 300
3. Doxorubicin Farmitalia Dry powder with lactose
and 0.02% hydroxybenzoate
- dissolve H2O to 2mg/ml 580
4. Etoposide Bristol Myers
Squibb
Dry powder - dissolve in 50%
methanol:50% H2O at 1mg/ml 587
5. Cisplatin David Bull Preservative free 1 mg/ml 300
6. Cytarabine David Bull 20mg/ml preservative free 243
7. Vincristine David Bull Preservative free 1 mg/ml 923
8. Methotrexate David Bull Preservative free 2.5mg/ml 454
9. Dexamethasone
Phosphate David Bull Preservative free 4mg/ml 450
It was decided to investigate several drugs which have been
shown to have activity in lymphoma. The drugs were titrated in
logarithmically increasing concentrations in an attempt to find the
concentration that killed an arbitary 40% of the cells at 48hrs. At
the same time the mode of cell death was investigated to see if
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apoptosis were induced and then to see if any correlation between
this and any interaction with dantrolene existed.
9.2.2 Cell Line
The DOHH2 cells were cultured in RPMI base with 106/ml; 10ml
per flask (Falcon 3013E, 50ml) and incubated at 36°C, 5% CO2
with the chosen concentration of drug for 48hrs (4hrs in the case
of cisplatin and 4HC) prior to assessment of apoptosis.
9.2.3 Primary Culture
The lymphomas studied were cultured using the IL3/IL10 stromal
cell system. Cells were allowed to grow for 3-5 days prior to the
addition of an appropriate amount of cytotoxic drug or control to 4
wells of a Falcon 3047 (24 well) plate with initially 106 viable cells
per well in 2ml of medium. Cells were counted as described
previously. In the case of the two Hodgkin's lymphomas studied
FACS analysis was carried out to quantify the percentage
phenotypes of the cells post treatment as the number of T cells
was high and it was possible that all that had happened was that
these had been killed, lowering the total cell count.
9.2.4 Apoptosis
This was assessed using uptake of Floechst 33242 and Propidium
Iodide as described previously.
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9.3 Assessment of P-alvcoprotein mediated drug efflux influence bv
Nimodipine and Dantrolene
The drugs were surveyed using the DOHH2 cell line, primary
lymphoma culture cells and peripheral blood lymphocytes which
are known to express P-glycoprotein. P-glycoprotein can be
inhibited by many different drugs, the immunosuppressive drug
cyclosporin was used here for this purpose, the technique being
that described by Chaudhary et al157. The ability to excrete the
fluorescent dye DIOC2 was taken as evidence of a functional P-
glycoprotein system. Paralysis by cooling to 4°C, as an
alternative to cyclosporin was also used - the two methods
producing similar results.
Peripheral blood lymphocytes were prepared by centrifugation on
a Ficoll layer. The mononuclear layer was extracted and a pellet
prepared.
9.3.1 Lymphocyte Dyeloading
The pellet of cells was diluted in 10ml RPMI and 6pl of the dye
DIOC2 (100|ig/ml) leading to a final concentration of 0.06jig/ml.
The tubes were incubated for 25 minutes at 4°C - the low
temperature paralysed the efflux system allowing the cells to take
up the dye.
9.3.2 Dye Efflux
After 25 minutes incubation the tubes were spun at 1600g for 10
minutes and the supernatant discarded. The pellet of cells was
resuspended in 10ml of cold RPMI to wash the cells.
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The RPMI was discarded and the cells resuspended in RPMI with
10% FCS. 100jil of lymphocyte suspension were put in each of
two tubes and kept on ice to use as a control sample with low or
no dye efflux. The rest was divided and the drug under
investigation added and incubated in a final volume of 5ml of
RPMI and 10% FCS at 37°C for 3hrs. A set of duplicate samples
containing 2jimol/L of cyclosporin were used as positive controls
of P-glycoprotein inhibition.
9.3.3 FACS Analysis
After incubation, the samples were spun at 1000g, 10 minutes at
4°C. The lymphocyte pellets were resuspended in ice cold RPMI
and washed twice in this before analysis using a FACScan with
Lysys II software. Information was displayed on a histogram (see





M1 . M2 ,
M1 - Low Fluorescence
M2 - High Fluorescence
FL-1 Fluorescence
B) Maximum inhibition of P-glycoprotein
Count
M1 - Low Fluorescence
M2 - High Fluorescence
FL-2 Fluorescence
the more cells in the M1 band the more drug effluxed
spontaneously. A high M1:M2 ratio suggests a functioning
P-glycoprotein system. If cyclosporin or cooling to 4°C is
used the M-1 area contains minimal cells suggesting
inhibition of the system.
The following concentrations were tested in the cell line and





0, 15, 30, 60, 100 pmol/L
0, 0.25, 0.5 pmol/L
D-60; N-1 jimol/L
D-100; N-1 pmol/L
Controls: No drug at 4°C (No Efflux)
2jimol/L cyclosporin (Maximum Inhibition)
No drug at 37°C (Maximum Efflux)
Primary Lymphoma Culture: L304 (B cell - Small
Lymphocytic Lymphoma)
L503 (Follicle Centre
Lymphoma, Follicular Grade 1)
L1103 (Follicle Centre
Lymphoma, Follicular Grade 3)
5.3.4 Investigation of pulsed calcium channel blockade using
Nimodipine and Dantrolene with cytotoxic drugs
These studies were carried out using the DOHH2 cell line; 106
viable cells/ml were taken and grown in flasks (Falcon 3013E);
they were incubated with Nimodipine and Dantrolene prior to
washing in RPMI base and the addition of cytotoxic drugs with or
without calcium channel blockers. Cell counts were obtained
using a Coulter Counter. Viability was assessed by 0.2% trypan
blue exclusion, apoptosis was assessed using Hoechst 33342 and
Propidium Iodide.
(i) 72hr pulse calcium channel blockade
72hr pulsed calcium channel blockade using combined
nimodipine and dantrolene followed by addition of vincristine
(49hr) or cisplatin (4hr) was carried out 48hrs after drug
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incubation. The drugs were incubated either in the presence
or absence of calcium channel blockers (see Figure 2).
Figure 2
Drug + Calcium Channel Blocker
RPMI Base Alone (Control)
Drug + RPMI Base
72hrs 48hrs




2 concentrations of calcium channel blockers were used:
(i) Dantrolene 60|imol/L + Nimodipine 1pmol/L (DN-1).
(ii) Dantrolene 6pmol/L and Nimodipine 0.3pmol/L (DN-2).
Vincristine at a concentration of 1pmol/L and cisplatin at a
concentration of 10pmol/L were used.
(ii) 10 Dav Experiment to study prolonged pre and post calcium
channel blockade (Figure 3)
20ml of DOHH2 cells were taken (106/ml) and incubated
either with dantrolene and nimodipine (D/N) (6pmol/L and
0.3p.mol/L respectively) or in RPMI base alone. At 72hrs
both groups were washed 2 times and then a cytotoxic drug
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was added for 48hrs either in the presence of dantrolene and
nimodipine or not. After this the cells "were incubated for a
further 120hrs with channel blockers or control solutions and




























The Cytotoxics were not washed out after 48hrs, but remained in
the solution until analysis.
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9.4.1 Dose Finding Studies - see Table 2
Experiments were carried out in duplicate in most cases. The
concentrations required to kill >40% of cells at 24hrs or 48hrs is
recorded.
Table 2
Drug Concentrations to kill
>40% at 24hrs (jj.mol/L)
Concentration to kill












N/A - Not Available
The concentration chosen for future experiments usually lay
between the two readings. One exception was fludarabine for
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which evidence exists that more prolonged exposure with a
lower dose is more effective and so 1Ojimol/L was chosen.
An example is shown in Figure 4 showing the effect of 4HC on
DOHH2 cells.
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Figure 4: Assessment of apoptosis in the DOHH2 cell line 48
































9.4.2 Induction ofApoptosis - see Table 3
Not all drugs had similar profiles and although apoptosis was seen
at 24hrs and 48hrs, failure to find this - the cells simply being
necrotic, lead to sampling at earlier stages - at 1, 3, 6 and 12hr
post drug administration to see if an intervening apoptotic stage
had been missed. Despite this, neither doxorubicin nor cytarabine
appeared to induce apoptosis. In most cases results were
duplicated. The percentage of viable cells 72hrs post








Fludarabine 10 17 60
Doxorubicin 0.1 5 31
Etoposide 10 21 42
Cisplatin 10 27 40
Cytarabine 10 2 52
Vincristine 1 22 30
Methotrexate 10 21 44
Dexamethasone 1000 1 104
4HC 10 20 20
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9.4.3 P-glycoprotein Production.
Results were expressed as a proportion compared to that seen
with Opmol/L at 4°C - as 4°C is cold enough to inhibit the pump
and therefore all dye is thought to be retained. The maximum
inhibition with 2jimol/L cyclosporin - corresponds to this as well.
Peripheral blood lymphocytes: maximum inhibition with
cyclosporin or control at 4°C were equivalent. At 37°C 75% of
cells effluxed the dye suggesting a functioning pump (maximum
efflux).
The nimodipine and dantrolene samples all showed a distinct
decrease in fluorescent intensity compared to the controls and
were equivalent to the maximum efflux control at 37°C. This
demonstrated that nimodipine and dantrolene did not functionally
inhibit P-glycoprotein.
When DOHH2 cells were used in the assay, all the histogram
maps appeared the same as the 100% bright and maximum
inhibition controls. Since these demonstrated no efflux this
suggested that the cell line did not express P-glycoprotein. In the
three primary lymphoma cultures all samples and controls showed
no evidence of dye efflux. Thus these also do not appear to have
a functional P-glycoprotein system.
In conclusion neither dantrolene nor nimodipine affected P-
glycoprotein activity and as neither the DOHH2 cells nor the
primary lymphoma cultures appeared to express P-glycoprotein
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any synergy with cytotoxic drugs could not be due to P-
glycoprotein pump inhibition.
9.4.4 Combined calcium channel blockade and cytotoxic drugs
(i) 120hr experiment with cisplatin (Pt) and vincristine (VCR)
(Figures 5. 6 and 7^
Enhancement of the effect of both drugs is seen. In the case
of vincristine pre and post drug treatment with a high
concentration of dantrolene and nimodipine appeared most
effective, although the effect was modest reducing viable
cells from 25% to 9%. With cisplatin a similar effect was
seen although here the effect of high or low concentrations of
calcium channel blockers pre and post drug and
administration made little difference with viable cells reduced
from 40% to 24% with the lower concentration of calcium
channel blockers, and 40% to 30% with the higher.
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Figure 5: Analysis of cells at I20hrs following treatment with cisplatin and








Analysis of cells at 120hrs following treatment with vincristine





























Figure 7: Assessment of apoptosis in the DOHH2 cell line 48 hours
after treatment with Cisplatin or Vincristine alone or
preceded by 72 hour incubation with Dantrolene

















10 Dav Experiment (see Figure 8)
Analysis was delayed until 10 days had elapsed rather than 5 in
the previous experiment, because of evidence that the maximum
effect of the calcium channel blockers may take 7 days to be
seen. Here only a low concentration (dantrolene 6|imol/L,
nimodipine 0.3(imol/L) was studied. A small antiproliferative effect
(see graph) of the calcium channel blockers alone could be seen.
Both 4HC and cisplatin - the two strongest inducers of apoptosis
had evidence of enhancement by calcium channel blockade. The
difference between cytotoxic drug versus cytotoxic drug and
calcium channel blockade being significant (p = 0.013).
Doxorubicin and cytarabine showed much weaker enhancement
seen.
225
Figure 8: 10 Day analysis of calcium channel blockade versus

































Control DN2 4HC 4HC Pt Pt Dox Dox Cyt Cyt
+ DN2 + DN2 + DN2 + DN2
9.5 Drug sensitivity testing using the IL3/IL10 stromal cell system
9.5.1 Cells analysed 48hrs after drug exposure - single agents -
percentage versus untreated control - in the DOHH2 cell line and
two primary lymphoma cultures, L11 and L2
L11 - Follicle centre lymphoma grade 3








1 - Vincristine 10pmol/L ® ^e" Line
2 - Cytarabine 10pmol/L H L1105
3 - Dexamethasone 10p.mol/L H L211
4 - Methotrexate 10pmol/L
5 - Etoposide 1Opmol/L
6 - Doxorubicin 0.1pmol/L
7 - Fludarabine lOpmol/L
8 -4HC 1Opmol/L
9 - Cisplatin 10pmol/L
Overall the primary cultures seemed much less sensitive to
cytotoxic drugs than the cell lines. 3 drugs which are schedule
dependent - cytarabine, etoposide and fludarabine appeared
relatively ineffective especially in L11. Dexamethasone was the
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only drug which appeared consistently more effective in primary
culture than in the cell line.
9.5.2 Prolonged culture of fludarabine and etoposide (see Figure 10)
To see if prolonged drug exposure enhanced the activity of these
agents, both were left for 168hrs prior to analysis. The results












































F8 - Follicle centre lymphoma, follicular grade 1
F2 - Follicle centre lymphoma, follicular grade 1
L 9 - B cell small lymphocytic lymphoma
Prolonged exposure lead to greater cell killing compared to the
control in all cases. Interestingly the prolonged exposure showed
fludarabine to be a more active agent than 4HC, whilst etoposide
remained clearly weaker. Exposure timing may thus be critical for
some drugs in this system.
9.5.3 4HC versus 'CHOP' - see Figure 11
This experiment utilised a 120hr period of drug exposure prior to
cell counting. CFIOP was represented by 4FIC - 10jimol/L;
vincristine 10|imol/L; doxorubicin 0.1|imol/L; dexamethasone












































This result confirmed 'CHOP' to be superior to 4HC in the 5 day
study described.
Direct comparison of 4HC to dantrolene in low grade B cell
lymphoma (see Figure 12)
The results from the previous chapter with dantrolene were
compared to 4HC. This confirmed that single agent dantrolene at
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30-60(imol/L at a 5 day incubation was similar to 4HC in primary




















































9.5.5 Direct comparison of 4HC to dantrolene 60pmol/L and azumolene
6pmol/L in low grade B cell lymphoma (see Figure 13)
The results of dantrolene and azumolene have already been
shown but they are given with 4HC to allow a complete








































This result confirms azumolene and dantrolene to have significant
activity, though less than that of 4HC in these studies.
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Combined calcium channel blockade with dantrolene, nimodipine
and 4HC versus 4HC alone (see Figure 14)
This experiment was carried out in two samples. Low
concentrations of dantrolene and nimodipine were used (D -
































4HC + Dantrolene + Nimodipine
fl Dantrolene + Nimodipine Alone
L210 L1103
No obvious difference could be seen, but the drugs were
administered simultaneously - unlike the case in the DOHH2 cell
line.
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9.5.7 Direct comparison of cytotoxics versus azumolene in Hodgkin's
lymphoma (see Figure 15)
As CD15 and CD30 bearing cells make up only a small
percentage of total, the treated groups and control had total cell
counts and then FACS analysis to discover percentage of various
subgroups. No T cell depletion was carried out. As CD30 is a B
cell activated marker CD15 was used as the estimate of Hodgkin
cells as this antigen was not the subject to upregulation via the
cytokines/anti-CD40.
L1706 - Lymphocyte predominant HL.
L2005 - Lymphocyte predominant HL.
Experiment Design: The cells were cultured for 72hrs prior to







































■ A - Control
B B - Azumolene 10|j.mol/L
H C - Azumolene 20[imol/L
□ D - Vincristine 1(imol/L
□ E - 4HC 10fimol/L
L17 L20
On the basis of the total cell count azumolene 20(imol/L appears
equivalent to 4HC and vincristine. The phenotype of cultured
cells is shown below (see Table 4). The number of CD3 bearing
cells is much higher in the treated cells than in the untreated. The
same is true of the number of CD15 bearing cells suggesting the
number of B lymphocytes numbers reduced.
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Table 4
FACS Analysis L17 L20
ig Glneg CD3 CD15 CD30 CD3 CD15 CD30
Control 0 27 12 8 40 10 9
Azumolene 10|j.mol/L 1 60 18 5 54 15
Azumolene 20(j.mol/L 1 77 29 7 57 13 3
Vincristine 1|imol/L 1 82 40 22 69 26 6
4HC 10|j.mol/L 3 64 38 9 61 25 3
If the number of CD15+ve cells is calculated (%CD15 x total) cell
count, the results are as follows (see Figure 16):
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■ A - Control
H B - Azumolene 10{i.mol/L
11 C - Azumolene 20|imol/L
□ D - Vincristine 1p.mol/L
□ E - 4HC 10)j.mol/L
L17 L20
Using this analysis - all drugs appear less effective than when
total cell counts are used. Azumolene is superior to cytotoxics in
L20 and slightly less efficacious in L17. FACS analysis of treated
cells is particuarly useful if the number of malignant cells within
the culture is expected to be small and a fluorescently labelled
antibody can identify them.
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Discussion
The assessment of apoptosis using flow cytometry is not without
problems. Perhaps the gold standard still remains microscopy158.
When two methods morphology and DNA laddering are used -
discrepancies can occur159 and it has been suggested that more
than one method should be used.
There is evidence that drugs with very different actions are able to
induce apoptosis120'158 and the cell type may be more important
as to whether a cell undergo apoptosis or necrosis as opposed to
the inducing drug. The evidence that the drugs which were the
strongest inducers of apoptosis had this enhanced by calcium
channel blockade with dantrolene and nimodipine is equivocal.
Whilst the studies with vincristine and cisplatin in the DOHH2 cell
line suggested enhancement; in the 10 day experiment an
enhanced effect was seen for cytarabine and doxorubicin (poor
inducers of apoptosis) although this was weak; and may have
represented independent cell killing. It seems very unlikely that
the enhancement seen was due to P-glycoprotein inhibition.
Neither the primary lymphomas cultured nor the DOHH2 cell line
appeared to possess functional P-glycoprotein pumps and there
was no evidence from the peripheral blood lymphocytes (which
did) that either dantrolene or nimodipine affected it.
The interpretation of the primary culture work suggests that the
cytotoxics tested were less effective than in the DOHH2 cell line.
There was one major exception - dexamethasone which appeared
to have no activity in the cell line whilst activity was demonstrated
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in the primary culture. In one case methotrexate - a drug not
known to have significant activity in low grade lymphoma
appeared very effective (L211) this raises the question as to
whether drug sensitivity testing in patients relapsing may reveal
unexpected activity of certain drugs.
The timing of drug exposure appeared critical in certain cases
especially with fludarabine. Whilst a 48hr exposure revealed the
activity of 4HC - it failed to show activity of etoposide and
fludarabine. On prolonging drug exposure to 168hrs the effect of
fludarabine matched 4HC whilst although etoposide appeared to
have some activity this remained inferior to the other two drugs.
Experiments using a multidrug treatment - 4HC, doxorubicin,
vincristine and dexamethasone - to represent CHOP and
comparing this to 4HC alone showed it to be superior. This has
not been borne out in vivo where there is little evidence of
superiority of multidrug treatment over single agents - despite the
fact that the initial response rate is higher11.
Primary culture of solid tumours and haematological malignancies
for 72hrs in RPMI base160 has shown that different topoisomerase
II inhibitors have markedly different activities with non-cross
resistance being demonstrated - whether this translates into the in
vivo situation is unclear. It has been shown that drug sensitivity
testing is possible in HL although with only two samples studied it
is unclear how consistent results will be. The small number of
putative malignant cells has required that FACS analysis be
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carried out, lest the fall in total number be due to a fall in benign
lymphocytes
The testing of the ryanodine receptor antagonists in primary
culture was described in the last chapter - the results being
presented against single agent 4HC show the effect of these
agents. Both dantrolene and azumolene appear less effective
than 4HC although a higher concentration of azumolene needs to
be tested and a method to allow pulsed administration as in the
cell lines to see if this is more effective requires development.
The limited data presented suggest that there may be little benefit
in combining dantrolene and nimodipine with 4HC.
In conclusion based on initial cell line work to obtain appropriate
concentrations of cytotoxic agents it has been possible to show
that it is practical to evaluate drug sensitivity using the IL3/IL10
stromal cell system. In principle, a result would be available 10
days after the start of culture (3 days required to ensure the cells
start to proliferate, 7 days continuous drug administration -
necessary for fludarabine and etoposide). Such a time period to
wait to decide on therapy is acceptable in many cases of low
grade lymphoma. The correlation between the in vitro result and
in vivo response would require prospective evaluation, however
the fact that drugs which appear active in this system are known
to be active in vivo (4HC, fludarabine) whilst drugs like cisplatin




The treatment of both low grade B cell and Hodgkin's lymphoma continues
to be frustrating. In the low grade B cell lymphomas, the relapsing nature of
the diseases in most patients even with the most intensive chemo-radio
therapy regimens remains the main stumbling block. In Hodgkin's
lymphoma - the curability of a majority of patients has lead many to try to
find ways of maintaining the results whilst reducing toxicity; however, 20%
fail to respond adequately to initial therapy and for them further conventional
and even high dose chemotherapy still fail the majority of these patients.
The lack of new drugs with which to make a difference in outcome as
opposed to an alternative route to the current results has lead many to
conclude that further advances in the treatment of these diseases is unlikely
with conventional drugs and radiation and that a breakthrough will come
from some form of immune or gene therapy - both seem unlikely.
The potential of the CD80 system to contribute to immune regulation has
lead to renewed enthusiasm amongst those who favour tumour
immunotherapy. The work presented in this thesis suggest that such an
approach may be worth pursuing. Most low grade B cell lymphomas do not
express high levels of CD80 and induction in culture certainly appears to
make the cells more immunogenic as judged by a primary mixed lymphocyte
reaction. The further development of such an approach depends on the
ability to demonstrate a cytotoxic T cell response in autologous
lymphocytes. It may be possible to enhance this using IL2 or other
cytokines. Whether immunisation of patients with CD80 expressing
lymphocytes will form the initial therapy or perhaps as is more likely therapy
in those where substantial cytoreduction has been achieved with cytotoxics
remains to be decided.
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Perhaps the finding that azumolene and dantrolene have significant
cytotoxic activity is of most practical relevance. How these drugs are killing
the cells is unclear. Cell cycle interruption and a major induction of
apoptosis are unlikely at least in the cell lines studied and their relatively
slow action suggests a novel mechanism from conventional cytotoxics. The
link to bcl-2 expression - is tenuous although cells that produce high levels
of bcl-2 may be more sensitive. Azumolene in particular, in view of its
higher therapeutic ratio than dantrolene appears to deserve further
investigation in lymphoma management.
The use of primary lymphoma culture to predict drug sensitivity assumes
that a large choice of agents exists. Whilst it may be appropriate in
relapsing patients in whom first line drugs have failed, further data on
reproducibility of results will be required before such a technique can
become standard in planning therapy - in particular the ability to
demonstrate significant activity of one agent as opposed to another is
required.
The successful culture of Hodgkin's lymphoma comes at a time when there
is renewed interest into the origin and pathogenesis of this disease, the low
number of malignant cells within an affected node and the severity of
cytokine deregulation in advanced disease and its relative sensitivity to
cytotoxic agents all suggest that it may lend itself to different approaches in
therapy. The search for infective triggers is likely to increase and it may be
that as in some mucosa associated lymphoid tumours early treatment with
anti-infective agents may reduce the requirement for cytotoxic
chemotherapy.
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To conclude - the demonstration of a relatively flexible technique to store
and then culture lymphoma tissue from patients who have low grade B cell
or Hodgkin's lymphoma and the ability to use this to investigate new
approaches to therapy has been demonstrated. It is increasingly likely that
additional modalities of treatment will join chemo and radiotherapy in the
management of these diseases although their replacement by new
techniques seems on current evidence unlikely.
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Induction of CD80 expression in low-grade B cell lymphoma - a potential
immunotherapeutic target
J Shamash1, DC Davies2, A Salam1, AZS Rohatiner1, BD Young' and TA Lister'
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The CD80 antigen (B7) is expressed on activated B lympho¬
cytes. It is thought to be important in eliciting a T cell response
via its ligands CD28 and CTLA-4 when antigen is presented in
the presence of the MHC-1 peptide. Low-grade B cell lym¬
phomas analysed by flow cytometry express CD80 very poorly.
However, when grown in vitro using the IL-4/anti-CD40 stromal
cell culture system, following depletion of T and IgD-bearing
cells, a monoclonal B cell expansion occurs. Cells harvested
at days 10-13 express the antigen strongly, regardless of the
histological subtype of lymphoma. Further investigation of
CD80-mediated immune functions may be possible using this
system as a basis for testing immunotherapy.
Keywords: CD80 expression; low-grade lymphoma
Introduction
CD80' (B7) is an antigen of the immunoglobulin super family
which was originally described as being present on activated
B lymphocytes and not circulating B cell malignancies.2 It has
also been found on HTLV-1 infected T cells3 and cells of the
monocyte-macrophage series.4 It is a cell membrane protein
with a short, highly charged cytoplasmic tail;2 the extracellu¬
lar region resembles that of immunoglobulins. Recently, it has
been suggested that there might be three members of the B7
family (B7-1, B7-2 and B7-3)5 which could act as ligands to
CTLA-48 and CD28,7 both T cell antigens that bind B7.6 CTLA-
4 appears to be homologous to CD28 and has been cloned
to the same chromosomal region. Following T-B cell interac¬
tion over a period of 72 h the expression of different members
of the B-7 family may be induced.5 The studies described
below only examined CD80 (B7-1) expression.
In addition to the cell-cell interaction, the generation of T
lymphocyte immune responses requires soluble mediators
(cytokines) and accessory surface antigens. CD80 falls into the
latter group.9 The specificity of the T-B cell interaction
depends on the T cell receptor (TCR)/CD3 complex and the
antigen associated with class II MHC molecules on B cells;
without accessory molecule function full activation of the T
cells is not possible.8
Recent murine studies exploring the potential contribution
of accessory surface antigens are provocative: the introduction
of CD80 onto the cell membranes of murine melanomas is
sufficient to elicit a T cell response which can stop tumour
growth in v/Vo.10 Moreover, pre-vaccinating mice with such
cells prevents non-CD80 expressing melanoma cells of the
same type from growing when the same mice are re-chal¬
lenged 2 weeks later. In vitro expansion of low-grade lym¬
phoma, followed by induction of CD80 expression could
possibly be used as a source of cells which could be reinfused
as a form of 'immunotherapy'.
Initial reports on CD80 expression2 suggested that follicular
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lymphomas express CD80.2-9 It has been reported that IL-4
can upregulate CD80 following the stimulation of B lympho¬
cytes with anti-IgM or S. aureus Cowan (SAC).' Cross-linking
of the B cell antigen CD40 is an alternative way of activating
B lymphocytes. These will undergo long-term proliferation"
when incubated with irradiated fibroblasts (Ltk cells) trans-
fected with the human monocyte Fc receptor in the presence
of IL-4. A similar response has been observed in follicular
lymphoma cells.12
A study was therefore undertaken to confirm whether the
low-grade B cell lymphomas express the CD80 antigen and
whether or not they might be cultured for long enough to
allow transfection of the gene for CD80. The results below
suggest that transfection may not be necessary.
Materials and methods
Preparation of the lymphoma cell suspension
Twelve fresh specimens of confirmed low-grade lymphoma
(eight follicular, two lymphoplasmacytoid, one diffuse
centrocytic/centroblastic and one small lymphocytic, accord¬
ing to the Kiel classification) were dissected and cell suspen¬
sions prepared in RPMI 2%, fetal calf serum 5% (Gibco, Pais¬
ley, UK), gentamicin 40 /xg/ml (Roussel Laboratories,
Uxbridge, UK) and FHepes 25 mm (Gibco). Centrifugation on
Ficoll-Hypaque (Lymphoprep; Nycomed, Oslo, Norway) was
carried out to isolate the mononuclear cell fraction. This was
fluorescence immunophenotyped using anti-BB-1 (B7) at a
dilution of 1 :160/100 p.l/106 cells (Becton Dickinson,
Oxford, UK). Mouse IgG 1 (Becton Dickinson) was used as a
negative control. Phenotyping was performed on a FACScan.
Fluorescein isothiocyanate (FITC) staining was detected using
a 530/30 nm band pass filter and phycoerythrin (PE) staining
with a 585/42 nm band pass filter. Non-lymphoid cells were
gated out using forward and side scatter; 2000 cells were sur¬
veyed in all FACS analyses, the remaining cells being frozen
as a suspension in RPMI 2% with 20% fetal calf serum (Gibco)
and 10% DMSO (Fluka, Buchs, Switzerland) at a concen¬
tration of 2 x 107 cells/ml.
Thawing of cell suspensions
The cells were thawed and then resuspended in Dulbecco's
without phenol red (Gibco) with 1% bovine serum albumin
(Sigma, Poole, UK) and human immunoglobulin 0.5 g/l
(Sandoz Pharmaceuticals, Berne, Switzerland). They were
subsequently immunophenotyped using the following anti¬
bodies: IgG 1 FITC negative control (mouse) (Serotec, High
Wycombe, UK), anti-CD3 FITC (Dako), anti-CD14 FITC
(Dako), anti-lgD polyclonal F(ab)2 FITC (Dako). Two-colour
fluorescence was carried out using anti-kappa polyclonal
F(ab)2 FITC (Dako), anti-lambda polyclonal F(ab)2 PE (Dako).
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Depletion of T and IgD bearing cells
2 x 107 lymphoma cells were incubated with anti-lgD (Dako)
at a concentration of 100 /xl/1 ml/107 cells, anti-CD8 (Dako),
50 /xl/1 ml/107 cells and anti-CD4, 250 /xl/1 ml/107 cells.
Depletion ofT cells and IgD-bearing cells was carried out after
30-min incubation, with Dyna beads (R) (Dynal International,
Oslo, Norway) coated with anti-mouse Ig 1 ml/107 cells on a
rotating mixer at 4° C for 1 h followed by magnetic separation.
The remaining cells were immunophenotyped using the fol¬
lowing antibodies: IgG negative control, anti-CD3 FITC, anti-
lgD (Fab)2 FITC, anti-CD19 FITC, (all Dako). B7-24 (anti B7,
lgC2a kappa) (kindly supplied by Innogentics, Zwijnaarde,
Belgium),13 with a second layer anti-lgG2a FITC (kindly sup¬
plied by Dako), anti-CD11a FITC, anti-CD54 FITC, anti-CD58
FITC (kindly supplied by Dako), anti-CD54 FITC, anti-CD58
FITC (all Serotec), lgG2a FITC control (Dako), anti-BCL-2 FITC
(Dako) and anti-HLA-DR FITC (Dako).
Frozen: Phenotyping of the same lymphoma cells follow¬
ing thawing using the antibody B7-24 revealed a median
expression of 8% (s.d. 16) range 1-59%.
Cell viability
Viability of resuspended cells was assessed using 0.2% trypan
blue exclusion, a median viability of 95% (s.d. 3) was seen in
the 12 samples studied.
Confirmation of T and IgD bearing cell depletion and
clonality
The use of paramagnetic beads reduced the proportion of T
cells from a mean of 34% (s.d. 20) to 8% (s.d. 7) and IgD-
bearing cells from 22% (s.d. 17) to 6% (s.d. 7). The cells
showed light chain restriction using two-colour staining.
Comparison of B7-24 and BBI
BBI and B7-24 (Becton Dickinson) were compared using a
Raji cell line (known to express CD80) and were found to
be equivalent. B7-24 was used to assess CD80 expression in
resuspended cells because its lgG2a class allowed it to be
used in the presence of anti-CD40 (IgG 1) the second layer
anti-lgG2 being specific to the subgroup.
Bcl-2 and adhesion molecule expression
The cells showed low but significant expression of Bcl-2.
Median expression of CD11a, CD54 and CD58 was 34% (s.d.
19), 50% (s.d. 17) and 84% (s.d. 17) respectively.
Analysis of cells harvested after 10-13 days
Culture system
The cells were grown using the anti-CD40/IL-4 stromal cell
system.11 Mouse fibroblasts Ltk cells transfected with the CDw
32 Fc receptor obtained from the American Tissue Culture
Collection (with the permission of Dr KW Moore), were grown
to confluence in 24-well culture plates and then irradiated to
75 Gy. The lymphoma ceiis were suspended at a concen¬
tration of 5 x 105/ml, with 2 ml per well, in a growth medium
consisting of Iscove's modified Dulbecco's medium without
FCS (Gibco), with 50 /xg/ml human holotransferrin, 0.5% bov¬
ine serum albumin, 5 /xg/ml/ bovine insulin, long chain fatty
acids (c/s-9 octadecenoic, all c/'s 9,12 octadecadienoic, and
hexadecanoic acid all 1 /xg/ml (all from Sigma), 2% v/v fetal
calf serum, penicillin and streptomycin (Gibco) and gentam-
icin 40 /xg/ml (Roussel) anti-CD40 1 /xg/ml (Serotec) and hlL-
4 46 ng/ml (kindly provided by Schering Plough Research,
Bloomfield, NJ, USA). Cells were grown on the fibroblast
monolayer for 10-13 days before pippetting out and re-
phenotyping with the same antibodies.
Results
Initial phenotyping of samples
Fresh: Immunophenotyping of fresh samples revealed
poor expression of CD80. The median proportion of cells
expressing CD80 compared to control was 9% (standard devi¬
ation (s.d.) 24, range 2-89%). There was no evidence of a
discrete CD80-positive population of the cells.
Increased expression of CD80 was shown by a shift in medial
channel fluorescence, overall fluorescence increasing from
16.08 (s.d. 22) to 62.7 (s.d. 17) (individual results with corre¬
sponding histology are shown in Table 1 and Figure 1, two














Figure 1 Expression of CD80 (B7-24) compared to lgC2a control
isolated low-grade lymphoma B cells before and 10-13 days after
growth in the IL-4/anti-CD40 stromal cell culture system
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Table 1 Characteristics of cultured cells at days 10-13
Sample Histology CD3 IgD CD 19 Light CD80 CD11A CD54 CD58
chain
1 F 3 40 53 61 k 80 81 NA 99
2 F 9 2 68 95A 93 87 96 99
3 L 12 49 82 63k 98 53 98 100
4 S 4 3 51 99A 55 30 96 97
5 DC 6 33 58 69A 83 64 90 98
6 L 14 2 47 98A 87 49 66 95
7 F 2 41 57 95k 75 31 93 97
8 F 17 10 25 76k 58 39 68 94
9 F 7 18 50 78k 84 35 57 100
10 F 19 65 59 61 k 74 89 98 99
11 F 5 18 71 75k 88 61 91 99
12 F 9 50 65 NA 70 89 NA 99
F, follicular lymphoma; S, small lymphocytic; L, lymphoplasmacytoid; DC, diffuse centrocytic/centroblastic;
NA, not available
Details of individual lymphomas are shown in Table 2. Dur¬
ing culture a B cell proliferation occurred without evidence
of T cell overgrowth. The cells continued to show light chain
restriction on FACS analysis but there was a shift in phenotype
with an increase in CD19+ve cells and an upregulation in the
adhesion molecules studied. Expression of CD11 a, CD34 and
CD58 increased to 58% s.d. 22, 92% s.d. 14 and 99% s.d.
2, respectively.
In four lymphomas studied for HLA-DR expression this was
high at the end of the culture period.
Discussion
The stromal cell culture system offers a useful way of
investigating various aspects of the growth characteristics of
low-grade lymphoma and provides the potential to enhance
expression of certain antigens. Previously, it had only been
used to culture follicular lymphomas.13 It can now be con¬
firmed that it supports the growth of other low-grade B cell
malignancies. The ability to freeze cells and then resuspend
and grow them offers further flexibility.
In the past, a drawback has been the apparent change in
phenotype with a loss of mature cell antigens and the devel¬
opment of blast-like morphology;13 this has been seen in all
lymphomas studied here. However, the alteration and inter-
lymphoma variation of CD19 and IgD-bearing cells does not
appear to affect CD80 expression or the expression of the
adhesion molecules studied. Thus, IL-4 can induce CD80
expression in benign1115 and malignant B cells; cross-linking
of CD40 alone5 can also induce expression of it in benign
cells.
To achieve sustained proliferation of low-grade lymphoma
in vitro requires both IL-4 and CD40. There appears to be a
positive feed-back loop in the inter-regulation of CD80, IL-4
and CD40, in that ligation of CD80 with CD28 is itself able
to induce IL-4 secretion from B cells in benign lymphocytes.14
The current conventional treatment of low-grade lymphoma
is with relatively innocuous chemotherapy usually resulting in
the induction of a partial remission; more intensive therapy
gives a higher frequency of clinical remission but recurrence
or progression is usual. The concept of using a form of immun¬
otherapy to convert a clinical remission into cure is attractive.
















Figure 2 Two examples of low-grade lymphoma showing
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Table 2 Pre-culture B cell characteristics following IgD and CD3 bearing cell depletion
Sample Histology CD3 IgD CD19 Light CD80 CD11A CD54 CD58
chain
1 F 13 13 62 90k 0 36 68 87
2 F 7 0 27 97A 2 33 64 62
3 L 2 2 38 65k 6 53 37 42
4 S 7 1 84 99A 4 32 20 86
5 DC 5 2 35 92A 15 61 49 72
6 L 14 1 71 99A 38 26 49 72
7 F 4 6 45 96k 4 22 54 96
8 F 6 1 13 95k 10 12 44 43
9 F 3 8 70 97k 20 45 51 84
10 F 20 3 12 83k 24 23 23 65
11 F 2 16 70 97k 8 79 70 77
12 F 16 24 30 74k 59 64 75 NA
Abbreviations as for Table 1
vitro expansion and induction of CD80 expression might even
be considered provided that the patient's T cell competence
was confirmed.
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